



CEDARS-SINAI MEDICAL CENTER.

Surasak Phuphanich, M.D
Last revised: 8/16/2010



Johnnie L. Cochran, Jr. Brain Tumor Center

SURASAK PHUPHANICH, M.D., FAAN

Director, Neuro-Oncology Program

Professor of Medicine

Department of Neurology and Neurosurgery

Cedars-Sinai Medical center

8631 West Third Street Suite 410 East

Los Angeles, CA 90048

Office: (310) 423-4413 Fax: (310) 423-8189

E-mail Address: phuphanichs@cshs.org

Origin Native:

Bangkok, Thailand

Citizenship:

United States of America

Current Titles and Affiliations:

4/2007 - Present

Director, Neuro-Oncology Program

Professor of Medicine

Johnnie L. Cochran, Jr Brain Tumor Center

Department of Neurosurgery & Neurology

Cedars-Sinai Medical Center

Los Angeles, California

7/2008- Present

Professor of Medicine

Cedars-Sinai Medical center

Previous Academic and Professional Appointments:

9/2003- 4/2007

Professor of Hematology & Oncology

Clinical Program Leader, Neuro-Oncology

Emory University, School of Medicine, Atlanta, Georgia

7/2002 – 10/2003

Professor of Oncology & Neurology

Department of Inter-disciplinary Oncology

University of South Florida College of Medicine, Tampa, Florida

7/2000 – 6/2002

Associate Professor of Neurology & Oncology

Department of Interdisciplinary Oncology

University of South Florida College of Medicine, Tampa, Florida

7/1994 – 6/2000

Associate Professor of Neurology, Neurosurgery and Radiology

Department of Neurology

University of South Florida College of Medicine, Tampa, Florida

1/1984 – 6/1994

Assistant Professor of Neurology and Neurosurgery

Department of Neurology

University of South Florida College of Medicine, Tampa, Florida
7/1982 –12/1983

Assistant Research Neurologist

Department of Neuro-Surgery. University of California, San Francisco

7/1981 –6/1982

Clinical Instructor, Neurosurgery, University of California, San Francis

7/1980 –6/1981

Chief Resident, Neurology

University of Illinois Hospital, Chicago, Illinois

7/1978 –6/1980

Assistant, Neurology

University of Illinois Hospital, Chicago, Illinois

Previous Administrative and/or Clinical Appointments:

Administrative Appointments:

1992 - 1995

Neuro-Oncology Program Leader

H. Lee Moffitt Cancer Center and Research

Institute at the University of South Florida

1987 – 2003

Chief, Neurology Service

H. Lee Moffitt Cancer Center and Research

Institute at the University of South Florida

1985 – 2000

Director, Division of Neuro-Oncology, Department of Neurology

University of South Florida College of Medicine

Clinical Appointments:

2002- 2003

Full Membership in Residence H. Lee Moffitt Cancer Center

1995 - 2001

Associate Membership in Resident, H. Lee Moffitt Cancer Center

1993 - 1994

Membership in Residence, H. Lee Moffitt Cancer Center

1986 - 2003

Medical Staff, Active H. Lee Moffitt Cancer Center & Research Institute

1984 - 2003

Consultant, Neuro-Oncologist, St. Joseph's Hospital, Tampa, Florida

1984 - Present

Medical Staff, Active, Tampa General Hospital, Tampa, Florida

1984 - 2003

Consultant Neurologist, James A. Haley Veterans' Hospital, Tampa, Florida

1984 – 1994

Consultant Neurologist, University Community Hospital Tampa, Florida

Licensures/Boards:

State of California (A36229)
State of Georgia (053514)-inactive
State of Florida (ME0043483)-inactive
State of Illinois (036058266) – inactive

Specialty Boards:

Certification - March 1983
Diplomats of American Board of Neurology & Psychiatry (Neurology)

Education:

3/1973
B.Sc. Faculty of Science
Mahidol University, Bangkok, Thailand
3/1975
MD Faculty of Medicine
Ramathibodi Hospital, Mahidol University
Bangkok, Thailand

Postgraduate Training:

7/1981-12/1983
Clinical Research Fellow, Neuro-Oncology
Brain Tumor Research Center, Department of Neuro-surgery
University of California, San Francisco, California
7/1978-6/1981
Resident, Neurology
University of Illinois Hospital, Chicago, Illinois
7/1977-6/1978
Resident, Internal Medicine
Saint Francis Hospital, Evanston, Illinois
4/1975-5/1977
Rotating Intern, Resident, Internal Medicine & Psychiatry
Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Committee Memberships:

a. National and International

1997 - 2007
Executive Committee of NABTT
1997 - 2007
Chemotherapy/New Agents/Pharmacology, Minority & Gender Issues, Non
Astrocytoma/Non-therapeutic Initiatives, Response/Toxicity - Working Committees
NABTT Consortium
1996 – Present
Brain Tumor Committee, Eastern Cooperative Oncology Group
1994 - Present
Brain Committee, Radiation Therapy Oncology Group (RTOG)
1994 - Present
Intervention Neurology, American Academy of Neurology
1994 - Present
Neuro-Oncology, American Academy of Neurology (AAN)

b. Regional and State:

1996 - 2003

Medical Review Board

State of Florida: Agency for Health Care Administration
(Board of Medical Examiners)

1995 – 2003

Expert Medical Advisor (EMA)

Florida Department of Labor and Employment Security

c. Institutional:

2010-Present

Cancer Committee, Medical Staff Cedars-Sinai Medical Center

2009-Present

Cancer Advisory Council, SOCCI

Cedars-Sinai Medical Center

2009-2010

PRMC Protocol Review and Monitoring Committee

Samuel Oschin Comprehensive Cancer Institute (SOCCI)

Cedars-Sinai Medical Center

2008-Present

GCRC

Cedars-Sinai Medical Center

2004- 2007

Promotion & Tenure Committee, Department of Hematology-Oncology
Winship Cancer Institute, Emory University

2004- 2007

Executive Committee, Brain Tumor Program

Winship Cancer Institute, Emory University

2001 – 2003

Quality Management

Department of Interdisciplinary Oncology, College of Medicine

1994 – 1998

Clinical Research Council

H. Lee Moffitt Cancer Center & Research Institute

1994 – 2003

Academic Computing Committee

University of South Florida, College of Medicine

1993 – 1998

Research Committee

University of South Florida, College of Medicine

1993 – 1999

Clinical Affairs Council

H. Lee Moffitt Cancer Center & Research Institute

1992 – 1998

Managed Care Committee

University of South Florida, College of Medicine

1992 – 1998

Ambulatory Care Committee

H. Lee Moffitt Cancer Center & Research Institute
1991 - 1995
Equal Opportunity Committee, University of South Florida
1987 – 2003
Executive Committee
H. Lee Moffitt Cancer Center & Research Institute
1986 - 1992
Cancer Committee, University Community Hospital
1987 - 1992
Cancer Board Committee
H. Lee Moffitt Cancer Center & Research Institute
1986 - 1990
Pharmacy and Therapeutics Committee
H. Lee Moffitt Cancer Center & Research Institute
1987 - 1988
Program Committee, Hillsborough County Medical Association
1984 - 1987
Faculty Senate, University of South Florida
1984 - 1986
Cancer Committee, University of South Florida College of Medicine

Consultantships:

Warner Lambert/Parke Davis/Pfizer, Chiron Corporation, Cellegene Corporation, Schering Oncology Biotech, Direct Therapeutic Corporation, Peregrine Inc., Enzon Inc, MGI Pharma, Genetech Corp, Astra-Zenaca.

Editorships and Editorial Board:

2008 – Present
The Open Cancer Oncology Journal
2006 - Present
Current cancer Drug Targets
2004 - Present
Current Cancer Therapy Reviews
2003- Present
American Journal of Clinical Oncology

Manuscript Reviewer:

Reviewer, Neuro-Oncology
Reviewer, Journal of Neuro-Oncology
Reviewer, Journal of Neuro-imaging
Reviewer, Cancer
Reviewer, Cancer Investigation
Reviewer, Journal of the Moffitt Cancer Center
Reviewer, American Journal of Clinical Oncology

Honors and Awards:

2010
America's Top Doctors for Cancer (Castle Connelly Medical Ltd.)
2009
Top's American Oncologist Award (Consumer Research Council)

2008/2009

Patients' Choice Award (MDx Medical Inc.)

2007/2008/2009

America's Top Doctors for Cancer (Castle Connelly Medical Ltd.)

2007

Top Doctor in July issue of Atlanta Magazine

2006

Top's American Physicians Award (Consumer Research Council)

America's Top Doctors for Cancer (Castle Connelly Medical Ltd.)

2004 - 2007

Georgia Cancer Coalition Distinguished Clinical Investigator Professorial Award

2005

Recipient of NABTT Award for "Best Accrual to Clinical Trial" in Spring/Fall 2005

Recipient of NABTT Award for "Best Quality of Data Management" in Spring 2005

2003

Twenty years of Continuous Service Award, University of South Florida, College of Medicine

2003/2004

Recipient of NABTT Award for "Best Accrual to Clinical Trial"

2001/2002

Recipient of NABTT Award for "Best Accrual to Clinical Trial"

2001/2002

Scholar-Scientist Award, University of South Florida, College of Medicine, Department of Neurology

1998/1999

Recipient of NABTT Award for "Best Accrual to Clinical Trial" and "Best Quality of Data"

1997/1998

Scholar-Scientist Award, University of South Florida, College of Medicine, Department of Neurology.

1996

Clinician/Scholar of the Year Award, University of South Florida, College of Medicine, Department of Neurology

1996

Dedicated Service Award, University of South Florida, College of Medicine, Department of Neurology and H. Lee Moffitt Cancer Center and Research Institute.

1995

Marquis Who's Who in the World

1994

Marquis Who's Who in the South and Southwest

1993

Neuro-Oncology Award, Department of Neurology
USF College of Medicine

1992

Who's Who among Rising Young Americans

1986

Special Award, Founding Physician, H. Lee Moffitt Cancer Center and Research Institute

1984

Marquis Who's Who, Directory of Medical Specialists

1982 /1984

Research Fellowship Award, the Association of Brain Tumor Research

1982 /1983

Fellowship Award, American Cancer Society

1969

National Scholastic Achievement Award, The King of Thailand

Society Memberships:

2007- Present	American Association for Cancer Research (AACR)
1995 – Present	Society for Neuro-Oncology (SNO)
1989 - Present	American Society of Clinical Oncology (ASCO)
1978 – Present	American Academy of Neurology (Fellow) (AAN)
1996 – 2004	American Epilepsy Society (AES)
1986 – 1997	Florida Medical Association (FMA)
1986 – 1997	Hillsborough County Medical Association (HCMA)
1985 – 2001	American Society of Neuro-imaging (ASN)
1984 – 2001	Society for Neuro-Science (Tampa Bay Chapter)
1988 - 1990	Southern Association of Oncology (Founder)
1985 - 1990	Southern Medical Association (SMA)
1977 - 1982	American College of Physicians (ACP)

**Organization of National or International Conferences:
(Administrative and Sessions as Chair)**

1. Course Director on "The First Annual Update in Neuro-Oncology 1985", Tampa, FL, February, 1985.
2. Chairman, Symposium on Brain Tumor Section, International Symposium on Cancer Biology and Therapeutics, Tampa, FL, January 26, 1986.
3. Chairman, Symposium on Brain Tumor Imaging at the Ninth Annual Meeting of the American Society of Neuro-imaging; Clearwater Beach, FL, February 21-25, 1986.
4. Course Director on "The Second Annual Update in Neuro-Oncology 1986", Clearwater Beach, FL, March 14-15, 1986.
5. Course Director on "The Third Annual Update in Neuro-Oncology 1987", St. Petersburg Beach, FL, February 24-25, 1987.
6. Course Director on "The Fourth Neuro-Oncology Update 1989", Grand Cayman Island, British West Indies, May 27-29, 1989.
7. Course Director on "The Fifth Update in Neuro-Oncology", Harbor Island, Tampa, Florida, October 30, 1993.
8. Course Director on "Neuro-Oncology: State of the Art 2004", Emory Winship Cancer Institute at JW Marriott Buckhead, Atlanta, Georgia, May 22, 2004.
9. Course Director on "Neuro-Oncology: State of the Art 2005", Emory Winship Cancer Institute at Intercontinental Buckhead Hotel, September 30 – October 1, 2005.
10. **Course Director on "Advances in Neurology /Neurosurgery 2009", Cedars-Sinai Medical Center at Ritz-Carlton Hotel, February 14-15, 2009**

Grant Support:

a. Active Support:

1. Principal Investigator on “A Phase I Trial of Tumor Associated Antigen-Pulsed Dendritic Immunotherapy for Patients with Brain Stem Glioma and Glioblastoma.” July 1, 07-11 Immunocellular Therapeutics Inc \$300,000
2. Principal Investigator on “A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Subjects to Compare the Efficacy of AZD2171 [RECENTIN™] Monotherapy and the Combination of AZD2171 with Lomustine to the Efficacy of Lomustine Alone.” AstraZeneca Oncology July 1, 2008- 2011, \$175,500.
3. Principal Investigator on “A Phase I/II Trial of BIBW 2992 With or Without Daily Temozolomide in the Treatment of Patients with Recurrent Malignant Glioma.” Boehringer Ingelheim. July 1, 2008-2011, \$191,000.
4. Principal Investigator on “Phase II Study of Azixa (MPC-6827) For the Treatment of Patients with Glioblastoma Multiforme . June 10, 2009-2010, \$269,750
5. Principal Investigator on BTTC08-01: “A Phase II Study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed Glioblastoma without MGMT promoter methylation.” December 2, 2009-2011, \$23, 339.80
6. Principal Investigator on “DF/HCC protocol #08-266, Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma” September 14, 2009-2011 \$65,000

b. Previous Support:

- a. **Private Foundation funded:** Georgia Cancer Coalition Award: Distinguished Cancer Scholar, 2004-2007, \$ 750,000.
- b. **Grants and Clinical Research Funded:**
 1. Co-Investigator on "Neuro-Endocrine Regulation of GH Secretion in CNS Irradiated Children", Eleanor Naylor Dana Charitable Trust, July 1, 1986 - June 30, 1988, \$299,137.
 2. Co-Investigator on "Establishment of a Murine Brain Tumor Model for the Evaluation of Interferon Brain Tumor Therapy", Biomedical Support Grant, April 1, 1988 - March 31, 1989, \$5,000.
 3. Co-Investigator on "Effect of Interferon on Human Glioma Protein Kinase C", Moffitt Cancer Research Grant, August 1992 - July 1993, \$30,000.
 4. Co-Investigator on "MRI Segmentation for Tumor Volume Measurements", NIH, March 1, 1993 - February 28, 1996, \$682,000.
 5. Co-Investigator on Validation of a Family Caregiver Quality of Life Measure, American Cancer Society Grant, April 1996 - March 1997, \$15,000.
 6. Co-Principal Investigator on Consortium Therapeutic Studies of Primary CNS Malignancies adult, NABTT, New Approaches to Brain Tumor Therapy, NCI December 1, 1997-2003, \$503,564.00. (RFA CA-97-002).
 7. Principal Investigator on "Clinical Trial of ImuVert", Cell Technology, Inc., Boulder, Colorado, May 1988 - May 1990, \$60,000.
 8. Principal Investigator on RTOG 89-05, "A Randomized Phase III Study of Conventional Radiation Therapy (RT) Versus Conventional RT and Bromodeoxyuridine (BUdR) for Tumors Metastatic to the Brain", Radiation Therapy Oncology Group, January 1, 1990 - December 31, 1992, \$8,000.
 9. Principal Investigator on RTOG 90-06, "A Phase III Comparison of Hyper fractionated Radiation Therapy (RT) with BCNU and Conventional RT with BCNU for Supratentorial Malignant Glioma", Radiation Therapy Oncology Group, January 1, 1991 – January 31, 1995, \$15,000.
 10. Principal Investigator on ATC 91-10, "A Controlled Phase III Study of FluosolR Plus BCNU vs. BCNU Alone in the Treatment of Recurrent Malignant Glioma", Alpha 6 Therapeutic Corporation, December 10, 1991-December 9, 1994, \$245,000.

11. Principal Investigator on BTCCG 8901, "Phase III Study of Treatment of Malignant Glioma with Surgery and External Radiotherapy and Intravenous BCNU vs. Surgery and External Radiotherapy and Intravenous BCNU Plus Cisplatin vs. Surgery and External Radiotherapy and Principal Investigator on RTOG 91-14, "Neuro-Psychological Evaluation for Glioma Patients on RTOG 90-06", Radiation Therapy Oncology Group, July 1992 - July 1993, \$600.
12. Principal Investigator on RTOG 9305, "A Phase III Trial Comparing the Use of Radiosurgery Followed by Conventional Radiotherapy with BCNU to Conventional Radiotherapy with BCNU for Supratentorial Glioblastoma Multiforme", Radiation Therapy Oncology Group, July 1994 - June 1996, \$15,000.
13. Principal Investigator on ECOG 2393, "A Phase II Study of Continuous Infusion BCNU and Cisplatin and External Beam Radiotherapy for the Treatment of Patients with Newly Diagnosed Glioblastoma Multiforme", Eastern Cooperative Oncology Group, June 1994 - June 1996, \$5,000.
14. Principal Investigator on RTOG 9404, "A Phase III Randomized Study of Radiotherapy with or without BUdR Plus Procarbazine, CCNU, and Vincristine (PCV) for the Treatment of Anaplastic Astrocytoma", Radiation Therapy Oncology Group, October 1994 - June 1996, \$15,000.
15. Principal-Investigator on ECOG 2389, "A Phase III Evaluation of Postoperative Radiation in Low Grade Intracranial Astrocytoma and Oligodendrogliomas", Eastern Cooperative Oncology Group, July 1994 - June 1996, \$3,000.
16. Principal Investigator on RTOG 9402, "A Phase III Intergroup Randomized Comparison of Radiation Alone Versus Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic Oligodendrogliomas", Radiation Therapy Oncology Group, July 1994 - June 1996, \$5,000.
17. Principal Investigator on ECOG 9005, "Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone in the Treatment of Unresectable Meningioma (Phase III)", January 1994 - June 1996, \$3,500.
18. Principal Investigator on "Depofoam Encapsulated Cytarabine (DTC 101) Multi-Center Clinical Study in Patients with Neoplastic Meningitis", DepoTech Corporation, October 1994 - June 1998, \$50,000.
19. Principal Investigator on, "A Pharmacokinetic Study of Depofoam Encapsulated Cytarabine (DTC-101) for the treatment of Neoplastic Meningitis in Patients with Leukemia, Lymphoma or Solid Tumors," \$60,000.
20. Principal Investigator on RTOG 9310, "Phase II Combined Modality Treatment of Primary Central Nervous System Lymphoma," Radiation Therapy Oncology Group, March 1995, \$3000.
21. Principal Investigator on MCC 11061, "STEPS: Study of Neurontin: Titration to Effect, Profile of Safety," Parke-Davis, June-December 1995, \$2,000.
22. Principal Investigator on MCC 11062, "ALERT: Adjunctive Lamictal in Epilepsy and Response to Treatment Study," Burroughs Wellcome, June 1995-April 1996, \$3,000.
23. Principal Investigator on AKL01-017, A Randomized, Double-Blind, Placebo Controlled, Phase II Study of RMP-7 in Combination with Carboplatin Administered Intravenously for the Treatment of Recurrent Malignant Glioma, Alkermes Corporation, February 1996 - December 1996, \$131,326.
24. Principal Investigator on NABTT 95-06, Phase II/I/II Clinical and Pharmacologic Study of 9-Amino-20 (S)-Camptothecin (9-AC) Administered as a 72 Hour Infusion in Adults with Recurrent or Progressive Malignant Glioma, June 1996 – June 1998.
25. Principal Investigator on British Biotech MCC 11363, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pivotal Trial of Marimastat in Patients with Glioblastoma Multiforme or Gliosarcoma Following Completion of Conventional First-Line Treatment, October 1996 – June 1999, \$80,000.
26. Principal Investigator on DepoTech-DTC96001/MCC-11365, A Phase IV Multi-Center Clinical Study of Depofoam Encapsulated Cytarabine (DTC 101) in the Treatment of Neoplastic Meningitis in Patients with Solid Tumors, Including Primary Brain Tumors October 1996 – June 1999, \$24,000.

27. Principal Investigator on NABTT 96-05, A Phase I Clinical and Pharmacological Evaluation of Phenylbutyrate in Patients with Refractory Malignant Glioma: Study of Continuous Exposure Oral Phenylbutyrate on a Three-Time Daily Schedule, January, 98 – December, 99, (MCC #11693).
28. Principal Investigator on NABTT 97-06, ISIS Pharm, Inc., Phase II Evaluation of ISIS (CGP64128A) Administered as a 21 Day Continuous Intravenous Infusion in Patients with Progressive or Recurrent High Grade Astrocytoma, May, 1998 – 1999.
29. Principal Investigator on Alkermes-RMP-7 “A Phase III Study of Neoadjuvant Intravenous Cereport and Carboplatin in the Treatment of Newly Diagnosed Glioblastoma Multiforme July 1998-June 2000, \$161,000.
30. Principal Investigator on NABTT 96-07, The Treatment of Primary Central Nervous System Lymphoma with High Dose Systemic Methotrexate, January 1999 – 2000.
31. Principal Investigator on Bayer-Mint Metrifonate Investigational Nationwide trial for the treatment of Alzheimer’s Disease, September 1997-September 1998, \$11, 250.
32. Principal Investigator on SUGEN SU101.015, “A Phase III Randomized Study of SU101 & Procarbazine for Patients with Glioblastoma Multiforme in First Relapse” January 1999 December 2000, \$189,000.
33. Principal Investigator on Agouon AG3340, “A Randomized Double-blind, Placebo-controlled Phase II Study of the Matrix Metalloprotease Inhibitor Prinomastat in combination with Temozolomide Following Radiation Therapy in Patients having Newly Diagnosed Glioblastoma Multiforme”, October 1999 – December 2001, \$80,000. (MCC #12151)
34. Principal Investigator on SkyePharma C0101-010 “A Randomized Clinical Study to determine the Patient Benefit and Safety of Depocyt®”, January 2001 – December 2003 (Cytarabine Liposome Injection) for the treatment of Neoplastic Meningitis, \$148,491.15 (MCC #12168).
35. Principal Investigator on Direct Therapeutics/Protocol #99-01 “Phase I/II Study of the Safety and Tolerability of DTI-015 in Patients with Recurrent Glioblastoma Multiforme Protocol 99-01 MCC# 12397” July 2000 – July 2003 \$128,273.
36. Principal Investigator on NABTT #9902 “Phase I/II Trial of Oxaliplatin as Neoadjuvant Treatment in Adults with Newly Diagnosed Glioblastoma Multiforme”, April 2001-03.
37. Principal Investigator (National Study Chairman) NABTT 2008 “A Phase and Evaluation of the Safety and Pharmacokinetics of Altrasentan in Adults with Recurrent Gliomas” MCC-12802 April 2002-04.
38. Principal Investigator (Investigator Initiative Trial) on Celgene Corp-CG000339 “Phase II study of Low dose Thalidomide and Temodar in Multiple Brain Metastasis MCC# 12672”. March 2002-03 \$30,000
39. Principal Investigator NABTT 2006 “Phase I Evaluation of the Safety of Karenitecin in the treatment of Recurrent Malignant Gliomas” MCC-12894 April 2002-04.
40. Principal Investigator on NABTT-0303 “Phase I/II Study of Alanosine (SDX-102) Patients with Methylthioadenosine Phosphorylase (MTAP)-Deficient High Grade Progressive or Recurrent Malignant Gliomas”, April 2004-06.
41. Principal Investigator on NABTT-2111 “A Phase I/II Trial of BMS-247550 for Treatment of Patients with Recurrent High-grade Gliomas” October 2003-05.
42. Principal Investigator on “Randomized Phase III Study of Enzastaurin HCl vs Lomustine in the Treatment of Recurrent, Intracranial GBM (Lilly Protocol H6Q-MC-JCBF)”. Eli Lilly and Company
43. Principle Investigator on “An Open-Label, Extended-Use Study of Human Corticotropin-Releasing Factor (hCRF) intended for patients who participate in the Dexamethasone-Sparing Studies NTI0501”. Neurobiological Technologies, Inc. June 2006 – June 2007, 139,190.
44. Principal Investigator on “A Phase III, Randomized, Open-Label Study of IV Edotecarin vs. Temozolomide or Carmustine (BCNU) in Patients with Glioblastoma Multiforme that had Progressed/Recurred after Alkylator-based (Neo) Adjuvant Chemotherapy”, Pharmacia/Pfizer, January 2004-06, \$96,961

45. Principal Investigator on “A Phase III Randomized, Open-label comparative Study of Standard Whole Brain Radiation Therapy with Supplemental Oxygen, with or without Concurrent RSR-13 (Efaxproxiral), in women with Brain Metastases from Breast Cancer”, Allos Therapeutics, Inc., March 2004-06, \$117,945.
46. Principal Investigator on “A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain edema in Patients with Malignant Brain tumor who require Chronic Administration of High-Dose Dexamethasone”, Neurobiological Technologies, Inc. April 2004-07, \$99,980.
47. Principal Investigator on “A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Temozolomide or Placebo Added to Whole Brain Radiation Therapy for the Treatment of Brain Metastases from Non Small Cell Lung Cancer, Schering Plough, April 2004-07, \$85,550.

Supervisory Teaching:

a. Medical Student Teaching

Moffitt Cancer Center, 1986–2003

University of South Florida, College of Medicine

Each month, one to three 4th year medical students rotated through Neurology Service at Moffitt Cancer Center as part of their clinical clerkship requirement. These medical students were under direct supervision by me, nine out of twelve months. During the academic years, I was the attending Neurologist from October, 1986 – August, 2003 and supervised about 100 medical students. I was also working with 2 medical students. Joseph Selph and Helen Hobbs for abstract presentation as following: **Phuphanich S, Selph J**, Snodgrass S, Sherman B, Entis S, Smith P, Brem S. Low Dose Thalidomide and Temodar as Salvage Therapy for Recurrent Malignant Gliomas. Seventh Annual Meeting of the Society For Neuro-Oncology, November 21-24, 2002, San Diego, CA. Neuro-Oncology 4:4, 374,2002 (Abst#240).

Phuphanich S, Hobbs H, Entis, S, Sherman B, Snodgrass S. Efficacy of Salvage Therapy with Cisplatin, VP-16 and Vincristine (CVV) for Recurrent Malignant Gliomas. 55th Annual Meeting of the American Academy of Neurology, April 1, 2003, Hawaii. Neurology 60:5 March 2003 (Suppl 1) Abst # P01.001 p A15.

Phuphanich S, Hobbs H, S. Entis B. Sherman R. Quiltz, M. Green, and S. Snodgrass. Salvage Therapy with Cisplatin, VP-16, and Vincristine (CVV) for Recurrent Malignant Gliomas as Alternative Treatment with PCV Chemotherapy. Eighth Annual Meeting of the Society for Neuro-Oncology, November 13-16, 2003, Keystone, Colorado. Neuro-Oncology 5:4, 354, 2003, (Abst# TA-26).

b. Graduate Program

Neurology Residency Program – Moffitt Cancer Center, 1986-2003 University of South Florida, College of Medicine, The first and second year Neurology Residents at University of South Florida rotated regularly through Neurology Service for inpatient and consultation at Moffitt Cancer Center as part of their Neuro Residency rotation. These residents were supervised by me directly for bed side teaching care for nine out of twelve months during these academic years.

Listed below are some of the approximately 90 Residents, who graduated from University of South Florida, College of Medical were under my direct supervision:

Agrawal Vikas, MD, **Matthew Baker, MD**, Lata Bansal, MD, Douglas Black, MD, Charles Brock, MD, Deborah Burke, MD, Ganesh Chari, MD, Thomas Digeronimo, MD, Paul Elliot, Denise Griffin, MD, **Marianne Jacob, MD**, Julie Jaques, MD, Lisette Mimenez, MD, **Sharon Johnston**, MD, Scott Knisley, MD, Carla Ledoux, DO, Josephine Lim, MD, Orland Maldonado, MD, Ali Malek, MD, Dave Malka, MD, **Charles Olivera,MD**, Sean Orr, MD, Arthur Pedregal, MD, Diane Pollock, MD, Maria Recio, MD, Nancy Rodgers-Neame, MD, Diego Rielo, MD, Mark Rubino, MD, Mohamed Shaleh, MD,

Mary Ellen, MD, Shriver, James Stevenson, MD, Douglas ,Terzigini, MD, Abraham Totah, MD, Frank Urban, MD, John Wilson, MD, Maria Carmen Wilson, MD, and Pravan Zala, MD.

Listed below are publications and abstracts published:

Phuphanich S, Jacobs M, Spiers A: Complete response of recurrent brain metastases in malignant melanoma to 5-FU and alpha-interferon therapy. J Neuroimaging 4:114-116, Jun 1994.

Phuphanich S, Jacobs M, Gonzalvo A, Murtagh FR: MRI of spinal cord radiation necrosis simulating recurrent cervical cord astrocytoma and syringomyelia. Surgical Neurology 45(4): 362-365, Apr 1996.

Baker M, Brem S, Daniels S, Sherman B, Phuphanich S. Complete Response of Recurrent Multicentric Malignant Glioma to Treatment with Oral Sodium Phenylbutyrate. J. Neurooncol 59 (3):239-42, September, 2002.

Jacobs M, Phuphanich S: Seizures in brain metastasis and meningeal carcinomatosis. Proceedings of the American Society of Clinical Oncology Annual Meeting, 1990. 9:96(373); 1990.

Johnston S, Phuphanich S, Ku N, Prockop L. Simultaneous bone metastases with meningeal gliomatosis as a progression from hypothalamic low grade astrocytoma and response by chemotherapy. J of Neuroimaging 6(1) 66:1996 The 19th Annual Meeting of the American Society of Neuroimaging San Francisco, California, March 19-22, 1996. The 7th International Symposium of the Pediatric Neuro-Oncology Washington D.C., May 15-18, 1996.

Johnston S, Phuphanich S, Ku N, Prockop L. Bone metastases with meningeal gliomatosis as a progression from hypothalamic low grade astrocytoma and complete response by chemotherapy. Ann Neurology 40(3) 489 (M2); 1996. The 121st Annual Meeting of the American Neurological Association, Miami Florida, October 13-16, 1996.

Olivera C, Bartley M, Ferrall S, Phuphanich S. Long-term malignant glioma survivors over ten years: prognostic factors. The 20th Annual Research Seminar, American Cancer Society, Orlando, Florida, April 5, 1997 Proc Am Soc Clin Oncol 16:407a(1450), 1997.

Radiology Residency Programs:

University of South Florida, College of Medicine. I also worked with Radiology Residents Dr. Crocker, Dr. Phillips, Dr. Inman and Dr. Nabors on the following publications and abstracts presentations:

Phillips WE, Velthuizen RP, Phuphanich S, Hall LO, Clarke LP, Silbiger ML: Application of fuzzy c-means segmentation technique for tissue differentiation in

MR images of a hemorrhagic glioblastoma multiforme. Magn Reson Imaging 13(2):277-290, 1995.

Phillips WE, Phuphanich S, Velthuizen RP, Silbiger ML: Automatic MR tissue characterization for 3-D MR imaging of the brain using fuzzy c-means of a glioblastoma multiforme. J Neuroimaging 5:171-177, July 1995.

Crocker D, Murtagh R, Silbiger M, Phuphanich S. Chemotherapy-induced multiple malignant meningioma in Hodgkin's lymphoma and 3-D tumor measurement. The 3rd Annual Neuro-Oncology Conference, London, England, April 19-20, 1993.

Iman N, Murtagh FR, Linden C, Phuphanich S, Prockop L: 3-D analysis of contrast enhanced MRI data in assessing the progress of therapy for intracranial tumors. J Neuroimaging 4(1):59; 1984. The 17th Annual Meeting of the American Society of Neuroimaging Los Angeles, California, February 23-24, 1994.

Nabors G, Murtagh FR, Phuphanich S, Berman C, Arrington J: Thallium-201 SPECT evaluation of malignant brain tumor vs. radiation necrosis with pathologic correlation. American Society of Neuro-Radiology Meeting Chicago, Illinois April 21-27, 1995.

Nabors G, Murtagh FR, Phuphanich S, Berman C, Arrington J: Thallium-201 SPECT evaluation of malignant brain tumor vs. radiation necrosis with pathologic correlation. American Society of Neuro-Radiology Meeting Chicago, Illinois April 21-27, 1995.

Lectureships: Seminar invitations, and visiting scientists, etc.

1. Recent Advances in Medical Therapy of Brain Tumors. CME on Update on Clinical Neurology; Tampa, Florida, March 24, 1984.
2. Current Therapy of Malignant Brain Tumors. Medical Oncology Conference at USF; Tampa, Florida, March 30, 1984.
3. Bromodeoxyuridine as a Radiation Sensitizer in the Treatment of Malignant Brain Tumors. Annual Meeting of the Association for Brain Tumor Research; Chicago, Illinois, April 10, 1984.
4. Management of Malignant Brain Tumors. The 110th Annual Meeting of the Florida Medical Association, Scientific Session, The Florida Society of Neurology Meeting; Lake Buena Vista Florida, May 11, 1984.
5. Update in Current Therapy of Malignant Brain Tumors. The Neuroscience Community of Orlando; Orlando, Florida, September 11, 1984.
6. Update in Treatment of Malignant Brain Tumors. Noon Conference; St. Petersburg Medical Clinic, St. Petersburg, Florida, September 28, 1984.
7. Management of Medulloblastoma in Children. Pediatric Grand Rounds; Orlando Regional Medical Center, Orlando, Florida, November 6, 1984.
8. Neurological Complications of Radiation and Chemotherapy. CME on Neuro-Oncology Update '85; Tampa, Florida, February 9, 1985.
9. Systemic Chemotherapy of Malignant Brain Tumors. CME on Neuro-Oncology Update '85; Tampa, Florida, February 9, 1985.
10. Neurological Complications of Neurofibromatosis. Annual Meeting of Neurofibromatosis Society, Florida Chapter; Tampa, Florida, September 28, 1985.
11. Multimodality Therapy for Malignant Brain Tumors. Symposium on Cancer Biology and Therapeutics: Clinical Correlation in Cancer and Central Nervous System; Tampa, Florida, January 21, 1986.
12. Radiation and Chemotherapy Effects on Malignant Brain Tumors: CT and NMR Correlations. Scientific Program, Ninth Annual Meeting of the American Society of Neuroimaging; Clearwater, Florida, February 25, 1986.
13. Current Therapy for Primary Malignant Glioma and Glioblastoma Multiforme. CME on the Second Annual Update in Neuro-Oncology, 1986; Clearwater Beach, Florida, March 15, 1986.
14. Management of Chemotherapy and Radiation Necrosis vs. Recurrent Brain Tumors. CME on The Second Annual Update in Neuro-Oncology 1986; Clearwater Beach, Florida, March 15, 1986.
15. MRI/CT Scans in Evaluating Primary Malignant Glioma Following Surgery, Irradiation and Chemotherapy: USF Experience. CME on The Third Annual Update in Neuro-Oncology 1987; St. Petersburg Beach, Florida, February 25, 1987.
16. Cancer Pain Management: The Annual Meeting of The Thai Physicians Association of America; Industry Hills, California, June 26, 1987.
17. Long-Term Survival in Malignant Glioma: Prognostic Factors. CME on The Fourth Neuro-Oncology Update 1989, Grand Cayman Island, British West Indies, May 27-29, 1989.
18. Advances in Medical Treatment of Brain Tumors, Clinical Neuroradiology Seminar, Key West, Florida, April 25-27, 1990.
19. Novel Approach to Brain Tumor Therapy, Martin Memorial Hospital Medical/Surgery Grand Rounds, Stuart, Florida, September 29, 1992.
20. Novel Approach to Brain Tumor Therapy, Sarasota Memorial Hospital Tumor Board Conference, Sarasota, Florida, March 23, 1993.
21. CNS Cancer, Annual Tampa Bay Hematology-Oncology Journal Club ASCO Review, Tampa, Florida, August 25, 1993.
22. Novel Approaches in Chemotherapy and Hormone Therapy for CNS CME. The Fifth Update in Neuro-Oncology, Tampa, Florida, October 30, 1993.
23. Novel Approach to Brain Tumor Therapy. Medical Grand Rounds, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, November 16, 1993.

24. Successful Treatment of Malignant Gliomas: Symposium on CNS Tumor. The 11th Asia-Pacific Cancer Conference, Bangkok, Thailand, November 19, 1993.
25. Phase III Clinical Trial for Treatment of Leptomeningeal Metastases: Evaluation of DepoFoam Encapsulated Cytarabine (DTC-101). Moffitt Grand Rounds, Moffitt Cancer Center, Tampa, Florida, May 5, 1995.
26. DepoFoam Encapsulated Cytarabine (DTC-101) for Neoplastic Meningitis. Internal Medicine Grand Rounds, Baptist Medical Center, Jacksonville, Florida, June 6, 1995.
27. Brain Tumors: Pitfalls of Diagnoses and Treatment. Neurology for the Primary Care Physician, Tampa General Hospital, Tampa, Florida, June 10, 1995.
28. Neurologic Complications of Systemic Cancer. Neurology Grand Rounds, University of South Florida, Tampa, Florida, September 15, 1995.
29. Novel Approach to Brain Tumor Therapy. Neurosurgery Grand Rounds, Tampa General Hospital, Tampa, Florida, April 19, 1996.
30. Complications of Chemotherapy and Radiation Therapy, Neurology Grand Rounds, University of South Florida, Tampa, Florida, May 24, 1996.
31. Novel Approach: Brain Tumor Therapy. Medical Grand Rounds, The Wallace-Kettering Neuroscience Institute, Dayton, Ohio, October 4, 1996.
32. Novel Approach: Brain Tumor Therapy. Neuro-Radiology Conference, Bay Front Medical Center, St. Petersburg, Florida, January 13, 1997.
33. Novel Approach: Brain Tumor Therapy. Medical-Oncology Grand Rounds, Halifax Medical Center, Daytona Beach, Florida, January 15, 1997.
34. Novel Approach: Brain Tumor Therapy. Medical/Surgical Grand Rounds, Sarasota Memorial Hospital, Sarasota, Florida, January 28, 1997.
35. Primary Brain Cancer: An Update. Medical/Surgical Grand Rounds, Winter Haven Hospital, Winter Haven, Florida, May 1, 1997.
36. Novel Approach: Brain Tumor Therapy. Oncology Conference, Holmes Regional Medical Center, Melbourne, Florida, June 5, 1997.
37. Neurologic Complications of Systemic Cancer. Neuro-Surgery Grand Rounds, Tampa General Hospital, Tampa, Florida, June 20, 1997.
38. New Approaches to Brain Tumor Therapy, Neurology Grand Rounds, Tampa General Hospital, Tampa, Florida, June 11, 1998.
39. New Directions for the Treatment of Alzheimer's, The Sixth Annual Meeting of TPAA, Southern Chapter, Tampa, Florida, November 27, 1998.
40. Paraneoplastic Syndrome, Neurology Grand Rounds, Tampa General Hospital, Tampa, Florida, January 21, 1999.
41. The New Direction for Treatment of Meningeal Carcinomatosis, Moffitt Grand Rounds, Tampa, Florida, April 16, 1999.
42. Advances In Neuro-Oncology, Annual Meeting, Florida Society of Neurology, Vero Beach Disney Resort, July 10, 1999.
43. Anti-angiogenesis, Grand Rounds, Tampa General Hospital, Tampa, Florida, March 9, 2000.
44. Chemotherapy for Patients with Brain Cancer, Moffitt Cancer Center Nursing Staff, Tampa, Florida, April 12, 2000.
45. Advances in Neuro-Oncology, Annual Meeting, Florida Society of Neurology, Naples, Florida, July 16, 2000.
46. Anti-angiogenesis therapy, Medical Grand Rounds, University of Miami, Sylvester Cancer Center. Miami, Florida, November 1, 2000.
47. Neuro-Oncology Update, Neurology Grand Rounds, Tampa General Hospital, Tampa, Florida, March 8, 2001.
48. Anti-Angiogenesis Treatment of Brain Cancer, Brain Tumor Board, Cedars Sinai Medical

- Center, Los Angeles, California, March 12, 2001.
49. Anti-Angiogenesis Treatment of Brain Cancer, Neurology Grand Rounds, University of California, Irvine Medical Center, Irvine, California, March 14, 2001.
 50. Neuro-Oncology Update, The Second Annual Van Den Noort Conference, Clinical Neuro-Science 2001, University of California, Irvine Beckman Conference Center, March 16, 2001.
 51. Management of Spinal Cord Compression and Meningeal Carcinomatosis, Neurology Grand Rounds, Tampa General Hospital, Tampa, Florida, March 29, 2001.
 52. Glioma: Incidence, Current Treatment, and Challenges. Temodar Advisory Board Meeting, Naples, Florida, June 9, 2001.
 53. Anti-Angiogenesis Treatment of Cancer, The 42nd Annual Scientific Congress, Medicine Chula International Medical Congress, The Imperial Queen's Park Hotel, Bangkok, Thailand, June 26, 2001.
 54. New Treatment for Stroke and Alzheimer's Disease, The 42nd Annual Scientific Congress, Medicine Chula International Medical Congress, The Imperial Queen's Park Hotel, Bangkok, Thailand, June 28, 2001.
 55. Biotherapy of Brain Tumor, Focus on Anti-angiogenesis. Neurology Grand Round, University of Chicago Hospital, Chicago, Illinois, December 13, 2002.
 56. Molecular Target of Brain Tumor Therapy, Neurology/Neurosurgery Grand Rounds, Stanford Medical Center, Stanford, California, March 1, 2002.
 57. Emerging Targeted Therapy of Brain Cancer, Pathology Grand Round, University of Colorado, Denver, December 12, 2002.
 58. Emerging Targeted Therapy for Brain Cancer, Cancer Director Seminar, Winship Cancer Center, Emory University, Atlanta, January 27, 2003.
 59. New Option of Treatment for Multiple Brain Metastases, Medical Oncology Video Conference, St Joseph's/ Candler Health system, Savannah, Georgia, March 12, 2003.
 60. Emerging Targeted Therapy for Brain Metastasis, Medical Oncology Conference, Watson Clinic, Lakeland, Florida, March 21, 2003.
 61. New Perspective in Management of Brain Metastasis and Leptomeningeal Disease, WCI Hematology and Oncology Grand Rounds, Winship Cancer Institute Conference Center, Atlanta, Georgia, October 29, 2003.
 62. Treatment of Neoplastic Meningitis: "What is the Standard of Care", Satellite Symposium - SNO Annual Meeting, Keystone Conference Center, Longs/Quandry Peak Conference Room, Keystone, Colorado, November 15, 2003.
 63. Molecular Targeted Brain Tumor Therapy, Neurosurgery Grand Round, Building B, Emory Clinic, Atlanta, December 18, 2003.
 64. New Perspective in Management of Brain Metastasis, Medical Grand Round, Macon Medical Center, Macon, Georgia, January 14, 2004.
 65. New Treatment Options in Leptomeningeal Disease, Neurology/Neurosurgery Grand Round, University of Alabama School of Medicine, Birmingham, Alabama, January 20, 2004.
 66. New Treatment Options for Leptomeningeal Disease, Medical Education Auditorium, Mercer University School of Medicine, Savannah, Georgia, February 20, 2004.
 67. Future Directions in Hematology and Oncology: "Emerging Targeted Therapy in Brain Tumor", The Cloister at Sea Island, Georgia. July 17 – 21, 2004.
 68. Post ASCO Review of Major Tumor Types, "Central Nervous System Tumors" Georgia Cancer Foundation, Emory Winship Cancer Institute, Atlanta, Georgia, August 14, 2004.
 69. Emerging Targeted Therapy in Brain Tumor, Neurology Grand Round, Emory University Brown Auditorium, Atlanta, Georgia, October 8, 2004.
 70. Novel Approached to CNS Malignancy 2005, CME Boca Raton Community Hospital, Bond Asian Fusion, Boca Raton, Florida, January 18, 2005.

71. Emerging Molecular Targeted Therapy for Brain Cancer, Oncology Tumor Board, Boca Raton Community Hospital, Boca Raton, Florida, January 19, 2005.
72. Management of Metastatic Brain Cancer and Leptomeningeal Disease 2005, Neurology/Neurosurgery Grand Round, The University of South Florida College of Medicine, Tampa General Hospital, Tampa, Florida, February 4, 2005.
73. New Diagnostic & Treatment of Brain Metastasis and Leptomeningeal Disease, Neurology Grand Round, Emory University Hospital Auditorium, April 29, 2005.
74. Emerging Therapies for Primary Tumors, Georgia Neurosurgical Society The Cloister at Sea Island, Georgia, May 28, 2005.
75. Central Nervous System Tumors, Post ASCO Review of Major Tumor Types, Georgia Cancer Foundation, Emory Winship Cancer Institute, Atlanta, Georgia, August 14, 2005.
76. New Diagnostic & Treatment of Brain Metastasis and Leptomeningeal Disease, Oncology Tumor Board Medical University of South Carolina, Charleston, SC, October 28, 2005.
77. ASCO Update & Advancing Care in Neoplastic Meningitis, Winter Mini Neuro-Oncology Symposium, Emory Cancer Institute at Paul's Restaurant, Atlanta, Georgia, February 22, 2006.
78. Clinical Trials Targeting the HIF Pathway and Hypoxia in Glioblastoma and New Protocol Concept, Neuro-Oncology Tumor Board at Cedars Sinai Medical Center, Los Angeles California, June 21, 2006.
79. Treatment of Brain Metastasis and Leptomeningeal Disease 2006, Neurology Grand Round, Medical College of Georgia, Augusta, Georgia, June 28, 2006.
80. Central Nervous System Tumors, Post ASCO Review of Major Tumor Types, Georgia Cancer Foundation, Emory Winship Cancer Institute, Atlanta, Georgia, July 15, 2006.
81. Novel Approaches to CNS Malignancies, Winship Cancer Institute 2006, Kiawah Island, July 30 – August 3, 2006.
82. Molecular Targeted Therapy of Brain Tumor, Hematology-Oncology Grand Round, John Amos Cancer Center, Columbus, Georgia, February 27, 2007.
83. Emerging Molecular Targeted Therapy of Brain Cancer and Research at Cedars, Oncology Grand Round, Nevada Cancer Institute, Las Vegas, January 11, 2008.
84. New Approaches to Low Grade and High Grade Glioma, Multidisciplinary Approach in Neuro Oncology Symposium, Bangkok Convention Center at CentralWorld, , Ramathibodi Hospital, Mahidol University, Ministry of Foreign Affairs, Thai Physicians Association of America, Bangkok, Thailand, February 1, 2008.
85. Advances in Management of Metastatic Brain Cancer and Leptomeningeal Disease, Multidisciplinary Approach in Neuro-Oncology Symposium, Bangkok Convention Center at Centra World, Ramathibodi Hospital, Mahidol University, Ministry of Foreign Affairs, Thai Physicians Association of America, Bangkok, Thailand, February 1, 2008.
86. Molecular Targeted Therapy for Brain Cancer, Multidisciplinary Approach in Neuro-Oncology Symposium, Bangkok Convention Center at CentralWorld, , Ramathibodi Hospital, Mahidol University, Ministry of Foreign Affairs, Thai Physicians Association of America, Bangkok, Thailand, February 1, 2008.
87. Emerging Molecular Targeted Therapy for Brain Cancer, Hematology-Oncology Grand Round, Cedars-Sinai Medical Center, February 12, 2008.
88. Pitfall in Diagnosis of Brain tumor and Treatment of Low Grade Glioma, Neurology Grand Round, Cedars-Sinai Medical Center, March 7, 2008
89. Emerging Molecular Targeted Therapy for Brain Cancer, Research Seminar at Sidney Kimmel Cancer Center, San Diego, March 26, 2008.
90. Emerging Molecular Targeted Therapy of Brain Cancer, Pathology Grand Round, Cedars- Sinai Medical Center, August 29, 2008.
91. Future Direction of Molecular Targeted Therapy for Brain Cancer, Neurosurgery Grand Round, Cedars-Sinai Medical Center, October 10, 2008.

92. Novel Bio-Chemotherapy for Brain Cancer: International Medical Meeting, Gabon, Africa
October 31, 2008
93. Bio-Chemotherapy, CME Advances in Neurology /Neurosurgery 2009, Ritz Carlton, Marina Delray,
February 14, 2009
94. Personalized Medicine for Brain Cancer, Hematology-Oncology Grand Round, Cedars- Sinai Medical
Center, September 22, 2009.
95. Personalized Medicine for Brain Cancer: Vaccine Immunotherapy, Neurosurgery Grand Round,
University of California, Irvine, May 12, 2010
96. Future Directions in Nanomedicine, BBB Modification and Vaccine Immunotherapy for Brain Cancer
Neuro-Oncology Conference, University of California, San Diego, May 14, 2010

Community Service

1. Television Interview, WXFL Channel 8, "Brain Tumor Treatment Center", **Tampa Bay Today
Program, July 15, 1985.**
2. Press Conference on "Brain Tumor Treatment Center", **June 22, 1985.**
3. Unit Leader, USF Medical Center United Way Fund Drive, 1985 and 1986.
4. Television Interview: **WTSP Channel 10: "Brain Cancer and Cellular Phones", September 7, 1994.**
5. Press Release, **St. Petersburg Times:" Brain Tumors on the Rise in Elderly", January 4, 1996 .**
6. Lunch with a Doctor, "The Increasing Incidence of Brain Tumors in Older Floridians", The Center
Club, Sheraton Grand Hotel, February 19, 1996.
7. Brain Cancer Survivor Day Mini-Symposium: Long-term Brain Cancer Survivors over 10
Years: Prognostic Factors, Moffitt Cancer Center, Tampa, Florida, June 10, 96.
8. Telephone Interview: Long-term Brain Cancer Survivors Over 10 Years: Prognostic Factors, **Oncology
News International, June 17, 1996 and feature article in October 1996:5:10.**
9. Telephone Interview: Long-term Brain Cancer Survivors Over 10 Years: Prognostic Factors,
Lakeland Regional Newspaper, June 27, 1996.
10. Article: Do Anti-convulsants compromise Brain Cancer Therapy? **Oncology Times, December 1996:
XVIII: 12.**
11. Medical Reviewer: Agency For Health Care Administration, State of Florida: Board of Medicine 1997
04.
12. Brain Cancer Survivors Day, September 23, 2000, Embassy Suites, Tampa, Florida.
13. Together In Hope, American Brain Tumor Association and Florida Brain Tumor Association, Wyndham
Westshore Hotel – Tampa, Florida, Jan 25 – 26, 2002.
14. Article: Salvage Therapy with Cisplatin, VP-16 and Vincristine (CVV) for recurrent malignant
Gliomas. **Oncology News International June, 2003, Vol 12, No. 6**
15. Brain Tumor Talk: Long-Term Survival (>10 yrs) from Brain Cancer is Possible. Moffitt Research
Center **MRC Auditorium June 18, 2003.**
16. Medical Break Through: Video/TV interview on Depocyt for the treatment of Meningeal
Lymphomatosis. **IVANHOE.COM May 31, 2003.**
17. Article: Glioblastoma: Why so Hard to Treat? **Oncology Times Vol XXV, No.19, October 10, 2003.**
18. Long Term Survival in Brain Cancer: Prognostic Factors, Brain Tumor Support Group, Winship Cancer
Institute, Room C3018, January 8, 2004.
19. Article: Winship Gets to the Bottom of Brain Tumors: **Atlanta Business Journal, Health Care
Quarterly, February 13-19, 2004.**
20. New Brain Tumor Targeted Therapy: Mini-Symposium New Brain Tumor Therapy for New
Millennium, Brain Tumor Action Week, **Emory Winship Cancer Institute C-5012, May 6, 2004.**
21. Long Term Survival in Brain Cancer: Southeast Brain Tumor Foundation, **Northside Hospital,
Atlanta, Georgia, May 10, 2004.**

22. Medical Break Through: Video/TV interview on Alpha-Interferon-2b for the treatment of Recurrent Glioblastoma. **IVANHOE.COM Dec 11, 2004.**
23. Brain Tumor Action Week Symposium “What’s New in Brain Tumor Therapy?” **Emory Winship Cancer Institute, C-5012. May 18, 2005.**
24. Team Education & Awareness Meeting and *Future Collaborations with Saint Thomas Hospital* and **Emory Winship Cancer Institute, Nashville, Tennessee, May 3-4, 2006.**
25. Brain Tumor Action Week Symposium Mini Symposium “*New Brain Tumor Therapy*” **Emory Winship Cancer Institute, C-5012. May 03, 2006.**
26. Annual Brain Tumor Patients Conference :Outsmarting Brain Tumors “ Clinical Trials” Cedars-Sinai Medical Center Auditorium on May 10, 2008.
27. Annual Brain Tumor Patients Conference :Outsmarting Brain Tumors “ Clinical Trials” Cedars-Sinai Medical Center Auditorium on June 13, 2009.
28. Lunch & Learn The Wellness Community, South Bay Cities Cancer Support, Education and Hope “Bio-Immunotherapy for Brain Cancer: A New Hope” on June 19, 2009.

Bibliography:

1. **Phuphanich S**, Edward ME, Levin VA, et al: Supratentorial malignant glioma in children: Survival and response of radiation and chemotherapy. J Neurosurg 60: 495-499, Mar 1984.
2. **Phuphanich S**, Levin EM, Levin VA: Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 10:1769-1772; Sept 1984.
3. **Phuphanich S**, Levin VA: Bioavailability of bromodeoxyuridine in dogs and toxicity in rats. Cancer Res 45:2387-2389; May 1985.
4. Levin VA, **Phuphanich S**, Hsiu-chih L, et al: Phase II study of combined BCNU, 5-Fluouracil, Hydroxyurea and 6-Mercaptopurine (BFHM) for the treatment of malignant gliomas. Cancer Treatment Report 70:1271-1274; 1986.
5. Guidi L, Specter S, **Phuphanich S**, et al: Inhibition of lymphocyte functions by serum from cancer patients. J Immunol Immunopharmacol 10(1):22-27;1990.
6. Clarke L, Velthuisen RP, **Phuphanich S**, Silbiger M: MRI: Stability of segmentation techniques for enhancing gliomas. Magn Reson Imaging 11:95-106;1993.
7. **Phuphanich S**, Ferrall S, Greenberg H: Long-term survival in malignant glioma: Prognostic factors. J Fla Med Assoc 80 (3):181-184; Mar 1993.
8. Jorgensen EV, Schwartz ID, Hvizdala E, Barbosa J, **Phuphanich S**, Shulman DI, Root AW, Estrada J, Hu CS, Bercu BB: Neurotransmitter control of growth hormone secretion in children after cranial radiation therapy. J Pediatr Endocrinol, 6(2): 131-142, Apr-Jun 1993.
9. **Phuphanich S**, Jacobs M, Spiers A: Complete response of recurrent brain metastases in malignant melanoma to 5-FU and alpha-interferon therapy. J Neuroimaging 4:114-116, Jun 1994.
10. Crocker D, Murtagh FR, **Phuphanich S**: Multiple malignant meningiomas following systemic chemotherapy for Hodgkins lymphoma - A three-dimensional analysis. J Neuroimaging 5:51-53, Jan 1995.
11. Phillips WE, Velthuisen RP, **Phuphanich S**, Hall LO, Clarke LP, Silbiger ML: Application of fuzzy c-means segmentation technique for tissue differentiation in MR images of a hemorrhagic glioblastoma multiforme. Magn Reson Imaging 13(2):277-290, 1995.
12. Phillips WE, **Phuphanich S**, Velthuisen RP, Silbiger ML: Automatic MR tissue characterization for 3-D MR imaging of the brain using fuzzy c-means of a glioblastoma multiforme. J Neuroimaging 5:171-177, July 1995.

13. Vaidynathan M, Clarke L, Velthuisen R, **Phuphanich S**, Bensaid A, Hall L, Bezdek J, Greenberg H, Trotti A, Silbiger M: Comparison of supervised MRI segmentation methods for tumor volume determination during therapy. Magnetic Resonance Imaging 13:5 719-728;1995.
14. **Phuphanich S**, Jacobs L, Poulos J, Vesely D: Hypoglycemia secondary to a malignant meningioma. Am J Med Sci 309:(6): 317-321, Jun 1995.
15. Werner M, **Phuphanich S**, Lyman G: The increasing incidence of primary malignant brain tumors in the elderly in Florida. Cancer Control: JMCC 2:4:309-34-1; Jul 1995.
16. Murtagh FR, **Phuphanich S**, Iman N, Clarke L, Greenberg H, Arrington J: Novel method for evaluation of treated brain tumors. Cancer Control: JMCC 2:4:293-299, Jul 1995.
17. Werner M, **Phuphanich S**, Lyman G: The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly. Cancer: November 78(9):1634-1643, 1995.
18. Velthuisen RP, **Phuphanich S**, Clarke LP, Hall LO, Bensaid AM, Arrington JA, Silbiger ML: Unsupervised measurement of brain tumor volume in MR images. J Magn Reson Imaging 5:594-605;Sept-Oct 1995.
19. **Phuphanich S**, Jacobs M, Gonzalvo A, Murtagh FR: MRI of spinal cord radiation necrosis simulating recurrent cervical cord astrocytoma and syringomyelia. Surgical Neurology 45(4): 362-365, Apr 1996.
20. **Phuphanich S**, Zachariah S, Zachariah B, Murtagh FR: MRI imaging of syrinx associated with intramedullary metastatic tumor and meningeal carcinomatosis. J Neuroimaging 6:115-117, Apr 1996.
21. Naidu K, Wiranowska M, **Phuphanich S**, Prockop L: Modulation of glioma cell growth and 5-lipoxygenase expression by interferon. Anticancer Research 16:3475-3482, Nov-Dec 1996.
22. **Phuphanich S**, Yung WKA, Scott C, Langer CJ: All trans-retinoic acid: A phase II radiation therapy oncology group study (RTOG-9113) in patients with recurrent malignant astrocytoma. J Neuro-Oncology 34(2):193-200, Sept 1997.
23. Vaidyanathan M, Clarke LP, Hall LO, Heidtman C, Velthuisen R, Gosche K, **Phuphanich S**, Wagner H, Greenberg H, Silbiger M. Monitoring tumor response to therapy using MRI segmentation. Magnetic Reson Imaging, 15(3), 323-334, 1997.
24. Wiranowska M, Ransohoff J, **Phuphanich S**, Weingart J, Brem H. Interferon-containing controlled release polymers for localized cerebral immunotherapy of glioma. J Interferon Cytokine Res 18:377-385: 1, Jun 1998.
25. Clark LP, Velthuisen RP, Clark M, Gaviria J, Hall L, Goldof D, Murtagh R, **Phuphanich S**, Brem S: MRI Measurement of Brain Tumor Response: Comparison of Visual Metric and Automatic Segmentation. Magn Reson Imaging 16(3): 271-279, 98.
26. Glantz MJ, Lafollette S., Jaeckle K., Shapiro W., Swinnen L., Rozental J., **Phuphanich S.**, et. al. A randomized trial of slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J. Clin Oncol 17(10): 3110-6, Oct 1999.
27. Glantz M, Jaeckle K, Chamberlain M, **Phuphanich S**, et. al. A Randomized Controlled Trial Comparing Intrathecal Sustained-release Cytarabine (DepoCyt®) to Intrathecal Methotrexate to patients with Neoplastic Meningitis from Solid Tumors. Clinical Cancer Res 5(11): 3394-402, Nov 1999.
28. Grossman SA, **Phuphanich S.**, Lesser G., Rozental J., Grochow LB, Fisher J., Piantadosi S.: Efficacy, Toxicity, and Pharmacology of Suramin in Adults with Recurrent High Grade Astrocytomas. J. Clin Oncol July 1:19(13):3260-6, 2001.
29. Jaeckle KA, **Phuphanich S**, Vandenbent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of Cytarabine. Br J Cancer Jan;84(2):157-63, 2001.
30. Jaeckle KA, Batchelor T, O'Day SJ, **Phuphanich S**, et al. An Open Label Trail of sustained-release Cytarabine (DepoCyt™) for the Intrathecal Treatment Solid Tumor Neoplastic Meningitis. J Neuro-Oncol May:57(3): 231-9, 2002.

31. **Phuphanich S**, Recurrent Multicentric Glioblastoma Multiforme Respond to Thalidomide and Chemotherapy. Oncology March 16 (3) :276-278, 2002.
32. Baker M, Brem S, Daniels S, Sherman B, **Phuphanich S**. Complete Response of Recurrent Multicentric Malignant Glioma to Treatment with Oral Sodium Phenylbutyrate. J. Neurooncol 59 (3):239-42, September, 2002.
33. Prados M, Schold S, Clifford Jr, Fine H, Jaeckle K, Hochberg F., Mechtler L, Fetell M, **Phuphanich S**, Feun L, Janus T, Downing G, Ford K, Graney W. A Randomized, Double-Blind, Placebo-Controlled, Phase-II Study of RMP-7 in Combination with Carboplatin Administered Intravenously for the Treatment of Recurrent Malignant Glioma. Neuro-Oncol 5(2):96-103, 2003.
34. Batchelor T, Gilbert M, Supko J, Nabors L, Grossman S, Lesser G, Mikkelsen T, and **Phuphanich S**. A Phase II Study of Weekly Irinotecan in Adults with recurrent Malignant Glioma: Final Report of NABTT 97-11 Neuro-Oncol 6 (1):21-7, 2004.
35. **Phuphanich S**, Brat DJ, Olson J: Emerging Delivery Systems and Molecular Targets of Mechanism-based Therapies for Glioblastoma Multiforme. Expert Review of Neurotherapeutics 4(4), 89-103, 2004.
36. Van Meir EG, Anita B, and **Phuphanich S**: Emerging Molecular Therapies for Brain Tumors. Semin Oncol 31 (Suppl 4): 38-46, 2004.
37. **Phuphanich S**, Recht L: Treatment of Neoplastic Meningitis: What is the Standard of Care? Expert Review of Neurotherapeutics 4(4) S11-S17, 2004.
38. Chiocca EA., Abbed KM., Tatter S., Louis DN., Hochberg, FH, Barker F., Kracher J., Grossman SA., Fisher J., Priet R., Rosenblum M., Mikkelsen T., Olson J., Markert J., Rosenfeld S., Nabors, LB., Brem S., **Phuphanich S.**, Freeman S., Kaplan R., Zwiebel J. A Phase I, Open-Label, Dose-Escalation, Multi-Institutional Trial of Intratumoral Injection with an EIB-Attenuated Adenovirus, ONYX-015, into Recurrent Malignant Gliomas. Molecular Therapeutic 10:5, 958-966, Nov, 2004.
39. **Phuphanich S**, Baker S, Grossman SA, Gilbert M, Fisher J, Carson K, and Carducci M. Oral Sodium Phenylbutyrate in Patients with Recurrent Malignant Gliomas: A Dose Escalation and Pharmacologic Study. Neuro-Oncol 7:2,177-182, April, 2005.
40. Brem S, Grossman S, Carson K, New P, **Phuphanich S**, Alavi J, Mikkelsen T, Priet R: Phase II trial of Copper Depletion as for the Angiosuppressive treatment of Newly Diagnosed Glioblastoma Multiforme. Neuro-Oncology 7,3, July, 246-253, 2005.
41. Levin VA, **Phuphanich S**, Yung WK, Forsyth P, Mastro R, Perry J, Elliott M, Baillet M: A multicentre, randomized, double blind, placebo (PB)-controlled trial of Marimastat (MT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) following completion of conventional first-line treatment". J. Neurooncol Jul;78(3):295-302 2006.
42. Gatcombe H, Lawson J, **Phuphanich S**, Crocker I. Treatment related myelitis in hodgkin's lymphoma following stem cell transplant, chemotherapy and radiation: a case report and review of the literature. J. Neurooncol 79(3):293-8. 15, 2006
43. Grossman SA, Supko J, Batchelor T, Lesser G, Mikkelsen, Alivi J, **Phuphanich S**, Carson K, Fisher J for the NABTT CNS Consortium: The Effect of Enzyme Inducing Anti-Seizure Drugs on the Pharmacokinetics and Maximum Tolerated Dose of Procarbazine Hydrochloride. Clinical Cancer Research 1:12(17):5174-81,2006.
44. **Phuphanich S**, Brock C: Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody. J. Neurooncol 81:67-69,2007.
45. **Phuphanich S**, Bernard M, Braeckman R and Chamberlain M: A Pharmacokinetic Study of intra-CSF(Cerebrospinal fluid) Encapsulated Cytarabine (Depocyt) for the treatment of Neoplastic Meningitis in patients with Leukemia, Lymphoma, or Solid tumors as part of a Phase III Study. J. Neurooncol 81:201-208, 2007.

46. Song JH, Tse MC, Bellail A, **Phuphanich S**, Khuri Fadlo, Kneteman NM, Hao C: Lipid rafts and non-rafts mediate TRAIL-induced apoptic and non-apoptic signals in non-small cell lung carcinoma cells. Cancer Research 67 (14), 6946-55, 2007.
47. **Phuphanich S**, Carson K, Grossman SA, Lesser G, Olson J, Desideri S, Mikkelsen T, Fisher J: A Phase I Evaluation of the Safety of Escalating Doses of Atrasentan in Adults with Recurrent Malignant Glioma. Neuro Oncol. Aug;10(4):617-623, 2008
48. Grossman SA, Supko J, Carson K, **Phuphanich S**, Batchelor T, Peereboom D, Nabors G, Lesser G, Desideri S, Hausheer F: Phase I Clinical Trial and Pharmacokinetic Study of Karenitecin in the treatment of Recurrent Malignant Gliomas: Neuro Oncol. Aug;10(4):608-616, 2008
49. Olson JJ, McKenzie E, Megan SM, Zhang Z, Brat D, and **Phuphanich S**: Phase I Analysis of BCNU Impregnated Biodegradable Polymer Wafers followed by Systemic Interferon alpha2b in Adult with recurrent Glioblastoma Multiforme. J. Neurooncol Dec;90(3):293-9, 2008
50. Bellail AC, Tse MC, Song, JH, **Phuphanich S**, Olsen JJ, Sun SY, Hao C. DR5-mediated controls caspase-8 cleavage and iniation of apoptosis in human glioblastomas. J. Cell. Mol. pp. 1-15,2009
51. **Phuphanich S**, Supko J, Carson K, Grossman S, Nabors L, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson J, NABTT CNS Consortium. A Phase I Evaluation of the Safety of Bortezomib with Biologic Proteosome 20S Activity Correlation and the Effects of Anticonvulsants in Adults with Recurrent Malignant Glioma. J. Neurooncol (2010) Mar 8. (Epub ahead of print)
52. Peereboom D, Carson KA, Supko J, Batchelor T, **Phuphanich S**, Lesser G, Mikkelson T, Grossman S: Phase I/II trial and Pharmacokinetic Study of Ixabepilone in Adult Patients with Recurrent High-grade Gliomas. J. Neurooncol 07, May 2010 (Epub ahead of print)
53. Lai A., Tran A., Phioanh L., Nghiemphu , Pope WB, Soli OE, Selch M, Filka E., Yong WH, Mischel PS, Liau LM, **Phuphanich S.**, Black K., Peak S., Green RM, Spier CE, Kolevska T., Polikoff J., Fehrenbacher L., Elashoff R., Cloughesy T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin Oncol (In press).
54. Mikkelsen T, **Phuphanich S**, Batchelor T, Fisher JD, Piantadosi S: Phase I/II trial of CI-980 in newly diagnosed glioblastoma multiforme – NABTT 9602. Neuro Oncol (Submitted).
55. New PZ, Mikkelsen T, **Phuphanich S**, Alavi J, Nabors L, Grossman SA, Piantadosi S, Rudek M, Fisher JD, A Phase I Study of Col-3 Administered on a Continous Oral Schedule in Patients with Recurrent High Grade Glioma: Results of the NABTT 9809 Clinical Trial. (In prep).
56. **Phuphanich S.**, Chamberlain M., Mikkelsen T, Ye X., Grossman SA, Batchelor T, Lesser G, Fisher J, Desideri S. New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium. A phase I study of SDX-102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas. (In prep).

Book Review:

1. Neuroimaging Clinics of North America, Brain Tumors, Norman Leeds, M.D., Guest Editor, November 1993. J Neuroimaging 1995.
2. Brain Tumors. Andrew H. Kayee and Edward R. Laws Jr. Edited by Churchill Livingstone. J. Neuroimaging 1996.

Abstracts and Presentations:

1. **Phuphanich S**, Edward ME, Levin VA, et al: Supratentorial malignant glioma in children: Survival and response of radiation and chemotherapy. Pediatric Section of the American Association of Neurological Surgeons, San Francisco, California, November, 1982. The 5th Conference on International Brain Tumor Research and Therapy, Pacific Grove, California, October 23-27, 1983.
2. **Phuphanich S**, Levin EM, Levin VA: Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. The 5th

- Conference on Brain Tumor Research and Therapy, Pacific Grove, California, October 23-27, 1983.
Chemical Modifiers of Cancer-Treatment, Canada, November 27 - December 1, 1983. J. Neuro-Oncol
35 (Suppl 1):S11, (abstr.#28), 1997.
3. **Phuphanich S**, Marton LJ, Levin VA, et al: An update of CSF polyamines in monitoring patients with medulloblastoma. J Neuro-Oncol 2(3):265;1984. The 2nd International Symposium on Biology of Brain Tumors, London,England, October 24-26, 1984.
 4. **Phuphanich S**, Marton LJ, Levin VA, et al: An update on the use of CSF polyamine level to monitor patients with recurrent medulloblastoma. Neurology 35(1):112;1985. American Academy of Neurology, The 37th Annual Meeting Program, Dallas, Texas, April 28 - May 4, 1985.
 5. **Phuphanich S**, Murtagh FR, Cahill D, Prockop LD: The effects of chemotherapy and radiation on malignant brain tumors: CT and MRI correlates. The 9th Annual Meeting of the American Society of Neuroimaging, Clearwater Beach, Florida, February 21-25, 1986.
 6. **Phuphanich S**, Boler Y, Prockop LD: The effects of combination chemotherapy: BCNU, 5-Fluorouracil, Hydroxyurea and 6-Mercaptopurine on recurrent glioblastoma multiforme with MRI/CT scan and clinical correlation. The 10th Annual Meeting of the American Society of Neuroimaging, Tampa, Florida, March 1, 1987.
 7. **Phuphanich S**, Murtagh FR, Prockop LD: MRI/CT in evaluating malignant brain tumors following surgery, irradiation and chemotherapy. Neurology 37(1):305;1987. American Academy of Neurology, The 39th Annual Meeting Program, New York, April 5 -11, 1987.
 8. Bercu BB, Schwartz ID, Hvizdala E, Barbosa J, **Phuphanich S**, Shulman DI, Root AW, Estrada J: Neurosecretory abnormalities secondary to cranial radiation therapy in children. The Endocrine Society, The 70th Annual Meeting Program. New Orleans,Louisiana, June 8-11, 1988.
 9. Bercu BB, **Phuphanich S**: Neurosecretory abnormalities in children with neuro-oncologic disease. American Cancer Society, Florida Division, 1988.
 10. **Phuphanich S**, Wongmongkolrit T, Jimenez L, Murtagh FR: MRI of meningeal gliomatosis. Proceedings of the American Society of Neuroimaging The 12th Annual Meeting, Orlando, Florida, February 23-26, 1989.
 11. **Phuphanich S**, Jacobs MB, Murtagh FR: MRI imaging of syrinx associated with intramedullary metastatic tumor. Proceedings of the American Society of Neuroimaging The 12th Annual Meeting, Orlando, Florida, February 23-26, 1989.
 12. **Phuphanich S**, Ferrall S, Wong T, Greenberg H: Long-term survival in patients with glioblastoma multiforme. Proceedings of the American Society of Clinical Oncology Annual Meeting, San Francisco, California, May 21-23, 1989.
 13. Jacobs M, **Phuphanich S**, Spiers A: Complete response of recurrent brain metastases in malignant melanoma to 5-FU and alpha-interferon therapy. Proceedings of the American Society of Clinical Oncology Annual Meeting, San Francisco, California, May 21-23, 1989, 8:93(364A);1989. Ann Neurology 26(1):182;1989. The 44th Annual Meeting of the American Neurological Association, New Orleans, Louisiana, September 24, 1989.
 14. Guidi L, Bartoloni C, **Phuphanich S**, et al: Inhibition of IL-2 production and of IL-2 dependent T cell proliferation by cancer patients' serum. Clin Expl Metastasis 7(2):251;1989.
 15. Wiranowska M, Roetzheim K, **Phuphanich S**, et all: Synergistic, antiproliferative activity of interferon (IFN) with chemotherapeutic 5-FU and BCNU against human glioma in vitro. The 7th International Congress of Immunology, West Berlin, July 30 - August 5, 1989.
 16. **Phuphanich S**, Jacobs M, Spiers A: Synergistic Effect Alpha-Interferon/ 5-FU and Cimetidine on Recurrent Brain Metastasis Secondary to Malignant Melanoma. J Neuro Oncol 7:S22;1989. The 8th Conference on Brain Tumor Research and Therapy, Zermatt, Switzerland, September 10-13, 1989.
 17. **Phuphanich S**, Wiranowska M, et al: Synergistic Effect of Alpha-Interferon and 5-FU Nitrosurea (BCNU) on Human Glioma and Melanoma Cell Lines. J Neuro Oncol 7:S31;1989. The 8th Conference on Brain Tumor Research and Therapy, Zermatt,Switzerland, September 10-13, 1989.

18. Wiranowska M, **Phuphanich S**, Prockop LD: 5-Fluorouracil (5 FU) and interferon (IFN) produce synergistic anti-proliferative activity of human glioma cells in vitro. Ann Neurology 26(1):182;1989 The 44th Annual Meeting of the American Neurological Association, New Orleans, Louisiana, September 24, 1989.
19. **Phuphanich S**, Ferrall S, Prockop LD: Long-term survival in patients with malignant glioma and brain metastasis: Prognostic factors. J Neurological Society of India 37:272(610D08);1989. The 14th World Congress of Neurology Annual Meeting, New Delhi, India, October 22-27, 1989.
20. Jacobs M, Murtagh FR, **Phuphanich S**: Radiation necrosis and syringomyelia: CT/MRI and pathology correlation. Neurology 40(1):149;1990. American Academy of Neurology 42nd Annual Meeting, Miami Beach, Florida, April 30 - May 6, 1990.
21. Jacobs M, **Phuphanich S**: Seizures in brain metastasis and meningeal carcinomatosis. Proceedings of the American Society of Clinical Oncology Annual Meeting, Washington, D.C., May 20-22, 1990. 9:96(373);1990.
22. **Phuphanich S**, Murtagh FR, Arrington J, Love L: CT guided aspiration/biopsy of cystic malignant brain tumors without stereotaxic procedures. J Neuroimaging 1:57(26);1991. The 14th Annual Meeting of the American Society of Neuroimaging, Orlando, Florida, February 5-10, 1991.
23. **Phuphanich S**, Murtagh FR, Arrington J, Love L: CT-guided aspiration biopsies of cystic lesions of the central nervous system. Annual Meeting of the American Society of Neuroradiology, Washington, D.C., June 9-14, 1991.
24. Jaeckle KA, Black KL, **Phuphanich S**, et al. Phase II multicenter trial of serratia biologic response modifier (S-BRM) in recurrent malignant astrocytomas (MA). J Neuro-Onc 12:242;1992. The 9th International Conference on Brain Tumor Research and Therapy, Asilomar, California, October 14-18, 1991.
25. **Phuphanich S**, Eikman E, Murtagh FR: Fluorodeoxyglucose positron emission tomography (FDG-PET) in long-term survival of malignant glioma. J Neuroimaging 2(1):55;1992. The 15th Annual Meeting of the American Society of Neuroimaging, San Francisco, California, February 17-21, 1992.
26. **Phuphanich S**. Successful treatment of recurrent pediatric malignant glioma with chemotherapy: Long-term remission by CT and PET study. Ann Neurol 32(3):470; 1992. The 21st Annual Meeting of the Child Neurology Society, New Orleans, Louisiana, October 22-24, 1992.
27. **Crocker D**, Murtagh R, Silbiger M, **Phuphanich S**. Chemotherapy-induced multiple malignant meningioma in Hodgkin's lymphoma and 3-D tumor measurement. The 3rd Annual Neuro-Oncology Conference, London, England, April 19-20, 1993.
28. **Phuphanich S**, Greenberg H, Murtagh FR, et al. Successful treatment of malignant glioma: Long-term remission over five years: CT/MRI/PET study. The 16th Annual Cancer Research Seminar for the Researchers of Florida, Orlando, Florida, March 6, 1993. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 16-18, 1993,12:181(520);1993. Proceedings of the 10th International Conference on Brain Tumor Research and Therapy, Norway, Sept 6-9, 1993.
29. Phillips WE, Velthuisen RP, Vilorio JE, **Phuphanich S**, Clarke LP, Silbiger ML, Murtagh FR: 3-D MR imaging segmentation of a high grade astrocytoma: MRI, gross and histopathology. College of Medicine Faculty Research Day, University of South Florida Office of Research and Graduate Affairs, April 17, 1993. The 33rd Annual Meeting of the American Society of Neuroradiology, Vancouver, British Columbia, May 1993.
30. Werner MH, **Phuphanich S**, Lyman G: Rising incidence of primary brain tumor in the elderly in Florida. Proceedings of the American Association for Cancer Research 35(3): 288 (1715), 94. Neurology 44 (2) 355p: 1994 The 46th Annual Meeting of the American Academy of Neurology, Washington, D.C., May 1-7,1994.
31. Yung WKA, Scott C, Fischback AJ, **Phuphanich S**, Langer CJ: All trans-retinoic acid: A Phase II radiation therapy oncology group study (RTOG 9113) in patients with recurrent malignant astrocytoma.

- Proceedings of the 30th Meeting of the American Society of Clinical Oncology, Dallas, Texas, May 14-17, 1994. 13: 3: 176 (495): 1994.
32. **Phuphanich S**, Murtagh FR, Prockop LD: Development of aggressive malignant meningiomas after systemic chemotherapy for lymphoma. J Neuroimaging 4(1):59; 1994. The 17th Annual Meeting of the American Society of Neuroimaging Los Angeles, California, February 23-24, 1994.
 33. Iman N, Murtagh FR, Linden C, **Phuphanich S**, Prockop L: 3-D analysis of contrast enhanced MRI data in assessing the progress of therapy for intracranial tumors. J Neuroimaging 4(1):59;1984. The 17th Annual Meeting of the American Society of Neuroimaging Los Angeles, California, February 23-24, 1994.
 34. **Phuphanich S**: Discontinuation of anti-epileptic drugs in patients after successful treatment of malignant brain tumors. Ann Neurology 36(2): 295; 1994 The 119th Annual Meeting of the American Neurological Association San Francisco, California, October 10, 1994.
 35. **Phuphanich S**, Ransohoff J: Successful withdrawal of anticonvulsants in patients with primary malignant brain tumors. Epilepsia 35: supplement 8; 1994 Annual Meeting of the American Epilepsy Society New Orleans, Louisiana, December 5, 1994.
 36. **Phuphanich S**, Berman C, Greenberg H, Murtagh FR, Prockop LD: Thallium-201 SPECT index of radiation necrosis and malignant brain tumor with pathological correlation and survival. J Neuroimaging 5: 68; 1995 , The 18th Annual Meeting of the American Society of Neuro-Imaging San Juan, Puerto Rico, March 7-11, 1995.
 37. Nabors G, Murtagh FR, **Phuphanich S**, Berman C, Arrington J: Thallium-201 SPECT evaluation of malignant brain tumor vs. radiation necrosis with pathologic correlation. American Society of Neuro-Radiology Meeting Chicago, Illinois April 21-27, 1995.
 38. **Phuphanich S**, Werner M, Lyman G: Increasing incidence of primary central nervous system lymphoma. Proceedings of the 31st Meeting of the American Society of Clinical Oncology Los Angeles, California May 20-23, 1995.
 39. Wiranowska M, Ransohoff J, **Phuphanich S**, Weingart J, Brem H. Interferon containing controlled-release polymers for localized cerebral immunotherapy of glioma. J Neuro-Oncology 28(1) 103;1996. The 11th International Conference on BrainTumor Research and Therapy, Napa, California, October 31 - November 3, 95.
 40. **Phuphanich S**, Velthuisen RP, Clarke LP. MRI segmentation methods for 3-D tumor volume analysis in patients with malignant brain tumors. J Neuro-Oncology 28(1) 103;1996. The 11th International Conference on Brain Tumor Research and Therapy, Napa, California, October 31 - November 3, 1995.
 41. Wiranowska M, Saporta S, Moore J, **Phuphanich S**, Nolan MR. Effect of interferon and nerve growth factor on glioma growth correlates with alteration of cell size. 1995 Annual Meeting of the Society for Neuroscience San Diego, California, November 11-16.
 42. **Phuphanich S, Brock C**, Roberts W, Prockop L. Neurological improvement after high-dose intravenous immunoglobulin therapy in paraneoplastic cerebellar degeneration associated with Anti-Purkinje cell antibody. Neurology 46(2) A129(P01.050):1996 The 48th Annual Meeting of the American Academy of Neurology San Francisco, California, March 23-30, 1996.
 43. **Johnston S, Phuphanich S**, Ku N, Prockop L. Simultaneous bone metastases with meningeal gliomatosis as a progression from hypothalamic low grade astrocytoma and response by chemotherapy. J of Neuroimaging 6(1) 66:1996 The 19th Annual Meeting of the American Society of Neuroimaging San Francisco, California, March 19-22, 1996. The 7th International Symposium of the Pediatric Neuro-Oncology Washington D.C., May 15-18, 1996.
 44. Glantz M, **Phuphanich S**, White C, et al. Treatment of leptomeningeal metastases with intra-CSF Depofoam encapsulated cytarabine. The 32nd Annual Meeting of the American Society of Clinical Oncology Philadelphia, Pennsylvania, May 18-21, 1996 Proc Am Soc Clin Oncol 15:160, 1996.

45. Ho H, Landau B, Brem S, **Phuphanich S**, Cahill D: The receptor for urokinase-type plasminogen activator: A marker of angiogenesis and malignancy in human gliomas. Proc Congr Neurol Surg, The 46th Annual Meeting, Montreal, September 28-October 3,p.406, (abstr #277), 1996.
46. Ho H, Brem S, **Phuphanich S**, Landau B, Cahill D, Kwaan H: The UPA receptor: a marker of angiogenesis and malignancy in human gliomas. Proc Soc Neuro-Oncol (abstr #11), 1996.
47. **Phuphanich S**, Lomartire M, DeConti R. Is early complete response in recurrent malignant gliomas treated with Cisplatin, VP-16 and Vincristine (CVV) related to anticonvulsants? Ann Neurology 40(3) 490 (M6); 1996 The 121st Annual Meeting of the American Neurological Association, Miami Florida, October 13-16, 1996.
48. Johnston S, **Phuphanich S**, Ku N, Prockop L. Bone metastases with meningeal gliomatosis as a progression from hypothalamic low grade astrocytoma and complete response by chemotherapy. Ann Neurology 40(3) 489 (M2); 1996 the 121st Annual Meeting of the American Neurological Association, Miami Florida, October 13-16, 1996.
49. **Phuphanich S**, Lomartire M, DeConti, Brem S. Effect of Dilantin on malignant gliomas treated with Cisplatin, VP-16 and Vincristine. The 1st Scientific Meeting of Society for Neuro-Oncology, Santa Fe, New Mexico, November 8-10, 1996.
50. Wiranowska M, Saporta S, Moore J, **Phuphanich S**. Effect of interferon and nerve growth factor on glioma cell growth. The 1st Scientific Meeting of the Society for Neuro-Oncology, Santa Fe, New Mexico, November 8-10, 1996.
51. **Phuphanich S**, Lomartire M, DeConti R. Effect of anticonvulsants on the outcome of malignant gliomas treated with Cisplatin, VP-16 and Vincristine (CVV). Epilepsia 37(5) 176(6.100); 1996 Fiftieth Annual Meeting of the American Epilepsy Society San Francisco, California, December 5-11, 1996 . The 20th Annual Research Seminar, American Cancer Society, Orlando, Florida, April 5, 1997.
52. Olivera C, Bartley M, Ferrall S, **Phuphanich S**. Long-term malignant glioma survivors over ten years: prognostic factors. The 20th Annual Research Seminar, American Cancer Society, Orlando, Florida, April 5, 1997 Proc Am Soc Clin Oncol 16:407a(1450), 1997.
53. Braechman R, **Phuphanich S**, Maria B, Kohn F. Pharmacokinetics (PK) of DepocytTM after intrathecal administration for the treatment of leptomeningeal metastases (LM). Proc Am Soc Clin Oncol 16:230a(810), 1997. The 12th International Conference on Brain Tumour Research and Therapy, Keble College, Oxford, United Kingdom, September 20-23, 1997.
54. Brem S, Ho H, Landau B, Kwaan H, **Phuphanich S**. Elevated levels of the receptor for Urokinase-type plasminogen activator in malignant human gliomas. The 12th International Conference on Brain Tumour Research and Therapy, Keble College, Oxford, United Kingdom, September 20-23, 1997.
55. Jaeckle K, Glantz M, Chamberlain M, **Phuphanich S**, Swinnen L, Campbell T, Maria B, LaFollette S and the DepoCyt Study Group. Treatment of carcinomatous meningitis (CM) with intra-CSF lipid particle injection Cytarabine (DepoCytTM) vs. Methotrexate (MTX). The 2nd Annual Meeting of the Society of Neuro-Oncology, Charlottesville, Virginia, October 31-November 2, 1997.
56. **Phuphanich S**. Successful withdrawal of anticonvulsants in patients with primary malignant brain tumors: MRI/CT/EEG correlation. Second Annual Meeting of the Society of Neuro-Oncology, Charlottesville, Virginia, October 31-November 2, 1997. The 50th Annual Meeting of American Academy of Neurology, Minneapolis, Minnesota, April 25-May 2, 1998, (Oral Presentation) Neurology 1998: 50(4): A353 S 52.
57. Brem S, Kumar R, Cahill D, **Phuphanich S**: Impact of MRI-guided neuronavigation for surgical resection of brain tumors, Third Annual Meeting of the Society of Neuro-Oncology, San Francisco, November, 1998.
58. Grossman SA, **Phuphanich S**, Lesser G, Rozental J, Grochow LB, Fisher JD, Piantadosi for the NABTT CNS Consortium. Efficacy, toxicity, and pharmacology of Suramin in adults with recurrent high grade astrocytomas. Proc Am Soc Clin Oncol 18:543, 1999.

59. **Phuphanich S**, Berman C, Pearlman J, Murtaugh F: Thallium-201 single-photon emission computed tomography index of radiation necrosis and malignant brain tumor with pathological correlation and survival. The 13th International Conference on Brain Tumor Research and Therapy, Hokkaido, Japan, October 4-6, 1999, Neuro- Oncology, October 1999, S116 (Abst # 207).
60. Mason W, Absey L, Aldeson L, **Phuphanich S**, et al. Phase III randomized study of SU101 & Procarbazine for patients with glioblastoma multiforme in first relapse. The First Annual Meeting of the Society for Neuro-Oncology, Scottsdale, Arizona, November 1999. Neuro-Oncology, October 1999, 324 (Abst #129).
61. Brem S, Kumar R, Voytek B, Cahill D, **Phuphanich S**: One-Day craniotomy for the safe, cost-effective removal of brain tumors, The 4th Annual Meeting of the Society of Neuro-Oncology, Scottsdale, Arizona, November, 1999, Neuro-Oncology, October 1999, 301 (Abst #31).
62. Howell SB, Jaeckle KA, **Phuphanich S**, et al: Intrathecal treatment of neoplastic meningitis Due to breast cancer with Depocyt. A slow-release formulation of cytarabine. Proc Am Soc Clin Oncol 19:100 a, 2000 (Abst #386).
63. Brem S, Grossman SA, New P, **Phuphanich S**, Priet R, Carson K: Phase II study of Penicillamine and reduction of copper for angiostatic therapy of glioblastoma: Preliminary safety and feasibility study. Proc Am Soc Clin Oncol 19: 172a, 2000 (Abst #666).
64. Baker MJ., **Phuphanich S**., Daniels S., Brem S.: Complete response of recurrent Multicentric Anaplastic Astrocytoma to Treatment with Oral Sodium Phenybutyrate. Neuro-Oncology, October 2000 (Abst #15), The Society of Neuro-Oncology, (5th Annual Meeting), November 9-12, 2000, Chicago, IL.
65. Mikkelsen T, **Phuphanich S**, Batchelor TT, Fisher JD, Piantadosi S, For the NABTT CNS Consortium. Phase I/II trial of CI-980 in newly diagnosed malignant glioma-NABTT 9602. Proc Am Soc Clin Oncol, 19:16a, 2000.
66. Fisher J, Carducci M, Baker S, **Phuphanich S**, Grossman SA, Gilbert M, Piantadosi S, Dose escalation study of oral sodium phenylbutyrate (PB) in patients (PTS) with refractory high grade astrocytoma (HGA): maximum tolerated dose (MTD), toxicity profile, pharmacology, and survival. Proc Am Soc Clin Oncol, 19:166a, 2000.
67. Mikkelsen T., **Phuphanich S**., Batchelor TT. Fisher JD. Piantadosi S. For the NABTT CNS Consortium. Phase I/II Trial of CI-980 in Newly Diagnosed Malignant Glioma NABTT 9602. Proc Am Soc Clin Oncol, 19:160a, 2000.
68. Brem S, Grossman SA, New P, **Phuphanich S**., Priet R, Carson K. Phase II study of penicillamine and reduction of copper, for angiostatic therapy of glioblastoma: preliminary safety and feasibility study. Proc AM Soc Clin Oncol, 19:172a, 2000.
69. Brem S., Grossman SA., **Phuphanich S**., Priet R., Carson K., For the NABTT CNS Consortium. Penicillamine and Copper Reduction for Treatment of Human Glioblastoma. EANO, 2000.
70. Brem S., Grossman SA., New P., **Phuphanich S**., Priet R., Carson K., for the NABTT CNS Consortium. Angiostatic Therapy of Glioblastoma using Penicillamine and Reduction of Copper: Preliminary Data of NABTT 9704 Phase II Clinical Trial. Society Neuro-Oncology, 2000.
71. Fisher J, Carducci M, Baker S, **Phuphanich S**., Grossman SA, Gilbert M, Piantadosi S. Dose escalation study of oral sodium phenylbutyrate (PB) in patients (PTS) with refractory high grade astrocytoma (HGA: maximum tolerated dose (MTD), toxicity profile, pharmacology, and survival. Proc Am Soc Clin Oncol, 19:166a, 2000.
72. **Phuphanich S**, Levin VA, Yung WK, Forsyth P, Mastro R, Perry J, Elliott M, Baillet M, “A mu with glioblastoma multiforme (GBM) or gliosarcoma (GS) following completion of conventional first-line treatment”. The 37th Annual Meeting of the American Society of Clinical Oncology Multi-centre, randomized, double-blind, placebo (PB)-controlled trial of Marimastat (MT) in patients, San Francisco, California, May 13, 2001 (oral presentation), Proc Am Soc Clin Oncol 2001.
73. **Phuphanich S**, Sherman B, Snodgrass S, Rojiani A, Brem S, “Synergistic effect of low dose thalidomide and chemotherapy for the treatment of recurrent multicentric glioblastoma multiforme”.

- The 14th International Conference on Brain Tumor Research and Therapy, The Grove Park Inn Resort , Asheville, North Carolina, May 27-29, 2001. Neuro-Oncology: S32, P132, October, 2001.
74. **Phuphanich S**, Levin VA, Yung WK, Forsyth P, Mastro R, Perry J, Elliott M, Baillet M, Phase II study of randomized, double-blind, placebo-controlled trial of Marimastat in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS) following completion of radiation therapy. The 14th International Conference on Brain Tumor Research and Therapy, The Grove Park Inn Resort, Asheville, North Carolina, May 27-29, 2001. Neuro-Oncology S32, P131, October, 2001.
 75. **Phuphanich S**. Synergistic Effect of Low Dose Thalidomide and Chemotherapy for the Treatment of Recurrent Multicentric Glioblastoma Multiforme. The 6th Annual Joint Cancer Conference of the Florida Universities, Opryland Florida, Orlando, Florida, Jan 31 – Feb 2, 2002.
 76. Grossman SA, Supko J, **Phuphanich S**, Batchelor T, Mikkelsen T, Powers P, Carson K, Priet R. Phase I/II Study of Oral Procarbazine in Patients with Recurrent High Grade Astrocytomas. The First Quadrennial World Federation of Neuro-Oncology Meeting, Washington, D.C., November 15-18, 2001. Neuro-Oncology, 3:4,358,2001,(Abst#365).
 77. Laterra J, Kleinberg L, Grossman S, Lesser G, Batchelor T, Lawson D, Mikkelsen T, **Phuphanich S**, Nabors B, New P, Piatadosi S, and Priet R. Phase II Trial of Systemic Suramin in Conjunction with Radiotherapy in Newly Diagnosed Glioblastoma. The First Quadrennial World Federation of Neuro-Oncology Meeting, Washington, D.C., November 15-18, 2001. Neuro-Oncology, 3:4 ,360, 2001, (Abst #372).
 78. Levin VA, **Phuphanich S**, Glantz MJ, Mason WP, Groves MD, Recht LD, Shaffrey M, Puduvalli V, Roeck B, Zhang MH, Collier MA. Randomized Phase II Study of Temozolomide (TMZ) with and without the Matrix Metalloprotease (MMP) Inhibitor Prinomastat in Patients (pts) with Glioblastoma Multiforme (GBM) Following Best Surgery and Radiation therapy. The 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 21, 2002 (Poster presentation) Proc Am Soc Clin Oncol 21:26a, 2002 (Abst #100).
 79. Hassenbusch SJ, Levin VA, Smith DA, **Phuphanich S**, Chen TC, Chamberlain MC, Cozzens JW, Paleologos N, Hariharan S, Zappulla RA, Pietronigro D. Multi-Center Phase I/II Trial of Stereotactic Injection of DTI-015 into Inoperable Recurrent Malignant Gliomas. Proceeding of The American Association of Neurological Surgeons (AANS), Chicago, Illinois, April 8-12, 2002. Proceeding of the 5th Congress of European Association of Neuro-Oncology (EANO), Florence, Italy, September 7-10, 2002.
 80. **Phuphanich S**, Snodgrass S, Wagner H. Unexpected Response of Recurrent Multiple Brain Metastases with ZD1839 (IRESSA), A Novel Oral EGFR-TK Inhibitor. Seventh Annual Meeting of the Society For Neuro-Oncology, November 21-24, 2002, San Diego, CA. Neuro-Oncol 4:4 , 2002
 81. **Phuphanich S**, Selph J, Snodgrass S, Sherman B, Entis S, Smith P, Brem S. Low Dose Thalidomide and Temodar as Salvage Therapy for Recurrent Malignant Gliomas. Seventh Annual Meeting of the Society For Neuro-Oncology, November 21-24, 2002, San Diego, CA. Neuro-Oncology 4:4, 374,2002 (Abst#240).
 82. Brem S, Snodgrass S, Staller A, Vrionis F, **Phuphanich S**, Pearlman J, Saatman D, Obadia M, Entis S. Interstitial Chemo to Prevent Recurrence of Brain Metastases. Seventh Annual Meeting of the Society For Neuro-Oncology, November 21-24, 2002, San Diego, CA. Neuro-Oncology 4:4, 364, 2002 (Abst#206).
 83. New P, Mikkelsen T, **Phuphanich S**, Alavi J, Nabors L, Grossman S, Priet R. A Phase I/II Study of Col-3 Administered on a Continuous Oral Schedule in Patients with Recurrent High Grade Glioma: Preliminary Results of the NABTT 9809 Clinical Trial. Seventh Annual Meeting of the Society For Neuro-Oncology, November 21-24, 2002, San Diego, CA. Neuro-Oncology 4:4, 373, 2002(Abst#237).
 84. Grossman S, Supko J, Batchelor T, Mikkelsen T, Alivi J, **Phuphanich S**, Carson K, Fisher J. The Effect of P450 Enzyme Inducing Anti-Epileptic Drugs On The Maximum Tolerated Dose and

- Pharmacology of Procarbazine. Seventh Annual Meeting of the Society For Neuro-Oncology, November 21-24, 2002, San Diego, CA. Neuro-Oncology 4:4, 347, 2002, (Abst#146).
85. Batchelor T, Lawson D, Mikkelsen T, **Phuphanich S**, Supko J, Carson K, Priet R, Grossman S. Phase I/II Trial of Oxaliplatin in Adults With Newly Diagnosed Glioblastoma Multiforme: NABTT 9902. Seventh Annual Meeting of the Society for Neuro-Oncology, November 21-24, 2002, San Diego, CA. Neuro-Oncology 4:4, 364, 2002 (Abst# 203).
 86. **Phuphanich S**, Hobbs H, Entis S, Sherman B, Snodgrass S. Efficacy of Salvage Therapy with Cisplatin, VP-16 and Vincristine (CVV) for Recurrent Malignant Gliomas. 55th Annual Meeting of the American Academy of Neurology, April 1, 2003, Hawaii. Neurology 60:5 March 2003 (Suppl 1) Abst # P01.001 p A15.
 87. **Phuphanich S**, Hobbs H, Entis S, Sherman B, Quiltz R, Green M, and Snodgrass S. Salvage Therapy with Cisplatin, VP-16, and Vincristine (CVV) for Recurrent Malignant Gliomas as Alternative Treatment with PCV Chemotherapy. Eighth Annual Meeting of the Society for Neuro-Oncology, November 13-16, 2003, Keystone, Colorado. Neuro-Oncology 5:4, 354, 2003, (Abst# TA-26).
 88. Monnell K, Minton S, and **Phuphanich S**. Complete Response of Intracranial Metastatic Breast Cancer to Trastuzumab (Herceptin) and Vinorelbine (Navelbine) Following Neoadjuvant Chemotherapy. Eighth Annual Meeting of the Society for Neuro-Oncology, November 13-16, 2003, Keystone, Colorado. Neuro-Oncology 5:4, 352, 2003, (Abst# TA-21).
 89. New PZ, Mikkelsen T, **Phuphanich S**, Alavi J, Nabors L, Grossman S, Pitantidose S, Rudek M, and Fisher J. A Phase I Study of Col-3 Administered on a continuous oral schedule in patients with Recurrent High-Grade Glioma: Results of the NABTT 9809 Clinical Trial. American Academy of Neurology, Neurology 62:7 (Suppl 5) PA543 April 2004.
 90. Brem S, Grossman SA, Carson KA, New P, **Phuphanich S**, Alavi JB, Mikkelsen T, and Priet R. Phase II trial of copper depletion as angiostatic treatment in newly diagnosed Glioblastoma Multiforme: Final Report. Proc Am Soc Clin Oncol, 23:114, 1530a, 2004.
 91. New PZ, Grossman S, Mikkelsen T, Batchelor T, **Phuphanich S**, Carson K, Fisher J, Craig M, and Cagnoni P. Evaluation of safety and tolerance of escalating doses of RSR-13 administered with dose of BCNU every six weeks in patients with recurrent malignant gliomas: Results of the Phase I NABTT 9806 clinical trial. Proc Am Soc Clin Oncol 23:115, 1533a, 2004.
 92. **Phuphanich S**, Grossman SA, Lesser G, Mikkelsen T, Carson K, and Fisher J. Phase I Evaluation of the Safety and Pharmacokinetics (PK) of Atrasentan in Adults with Recurrent Malignant Glioma: Preliminary Report. Ninth Annual Meeting of the Society for Neuro-Oncology, November 19-21, 2004, Toronto, Canada. Neuro-Oncol 6:4, 380, 2004 (Abst#TA-43).
The 41th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 14, 2003 (Poster Discussion presentation) Proc Am Soc Clin Oncol 23:16S, 120S, 2005 (Abst #1526)
 93. Lesser GJ, Grossman SA, Carson KA, **Phuphanich S**, Batchelor T, Peereboom D, Nabors LB, Supko J, and Hausheer F. Phase I study of Karenitecin in the treatment of recurrent malignant gliomas (MG). (Poster Discussion presentation) Proc Am Soc Clin Oncol 23:16S, 120S, 2005 (Abst #1527).
 94. Peereboom D, Batchelor T, Lesser G, **Phuphanich S**, Mikkelsen T, Carson K, Desideri S, Fisher J, and Grossman SA. NABTT 2111: A Phase I trial of BMS-247550 for patients with recurrent high-grade gliomas. (Poster Discussion presentation) Proc Am Soc Clin Oncol 23:16S, 129S, 2005 (Abst #1563).
 95. Olson JJ, Supko J, **Phuphanich S**, McKenzie E, and Grossman SA. Intratumoral pharmacokinetics determined with microdialysis in a patient with glioblastoma multiforme following systemic administration of high dose methotrexate. (Poster Discussion presentation) Proc Am Soc Clin Oncol 23:16S, 131S, 2005 (Abst #1569).
 96. **Phuphanich S**, McKenzie E, Greiner K, Shire K, and Olson JJ. Phase I Analysis of Systemic Interferon alpha Utilized with Gliadel in subjects with recurrent Glioblastoma Multiforme. Neurology 2006 (Abstr #P06.009)
 97. **Phuphanich S**, Supko J, Carson K, Grossman S, Nabors L, Mikkelsen T, Lesser G, Rosenfeld M,

- Desideri S, Olson J. Phase I trial of Bortezomib in adults with recurrent malignant glioma. Proc Am Soc Clin Oncol 24:18S, 2006 (Abst #1567)
98. **Phuphanich S**, Supko J, Carson K, Grossman S, Nabors L, Mikkelsen T, Lesser G, Rosenfeld M, Desideri S, Olson J. A Phase I evaluation of the safety of Bortezomib with biologic proteasome 20S activity correlation and the effect of anticonvulsants in adults with recurrent malignant glioma. Eleventh Annual Meeting of the Society for Neuro-Oncology, November 16-19, 2006, Orlando, Florida. Neuro-Oncol 8:4, 449, 2006 (Abst#TA-43).
 99. Nabors L, Rosenfeld M., Chamberlain M., **Phuphanich S**, Batchelor T., Supko J., Desideri S., Xiaobu Y., Wright J., Grossman S. A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). Proc Am Soc Clin Oncol 25:18S (June 20 Supplement), 2007 (Abst # 2058)
 100. **Phuphanich S.**, Chamberlain M., Mikkelsen T., Ye X., Grossman SA, Batchelor T., Lesser G, Fisher J., Desideri S. New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium. A phase I study of SDX-102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas. Proc Am Soc Clin Oncol 25:18S (June 20 Supplement), 2007 (Abst #2063).
 101. **Phuphanich S**, Chu R, Yu J, Black K. Phase I Study of gefitinib and rapamycin in adult patients with recurrent glioblastoma multiforme (GBM). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 24, 2007, San Francisco, California. Proc Am Soc Clin Oncol 26:18S (May 20 Supplement), 2008 (Abst # 2088)
 102. Peereboom D, Ye X, Nabors B, **Phuphanich S**, Chamberlain M, Lesser G, Desideri S, Grossman S. NABTT 0502: Phase II trial of Erlotinib and Sorafenib for Patients with recurrent or progressive glioblastoma multiforme. Twelfth Annual Meeting of the Society for Neuro-Oncology, November 15-18, 2007, Dallas, Texas. Neuro-Oncol 8:5, 525, 2007 (Abst#MA-37).
 103. Lai A., Nghiemphu P., Green R., Spier L., Peak S., **Phuphanich S**, Fehrenbacher L., Kolevska T. , Polikoff J., Cloughesy T. Phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme. Oral Presentation Proc Am Soc Clin Oncol 27:15S (May 20 Supplement), 2009 (Abst #2000).
 104. **Phuphanich S**, Rudnick J., Chu R., Mazer M., Wang H., Serrano N., Francisco F., Wheeler C., Singh M., Yu J. A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glioblastoma. Thirteenth Annual Meeting of the Society for Neuro-Oncology, November 21-23, 2008, Las Vegas. Neuro-Oncol 10:5, 815, 2008 (Abst #IM-31). Proc Am Soc Clin Oncol 27:15S (May 20 Supplement), 2009 (Abst #2032).
 105. Rudnick J., **Phuphanich S**, Chu R., Mazer M., Wang H., Serrano N., Francisco F., Black KL, Wheeler C., Yu J. A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. Proc Am Soc Clin Oncol 27:15S (May 20 Supplement), 2009 (Abst #2033).
 106. Recht LD, Mechtler L., **Phuphanich S**, Hormigo A., Hines V., Milsted R., O'Connor PC, Ryan RP, Wong ET. A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema. Proc Am Soc Clin Oncol 27:15S (May 20 Supplement), 2009 (Abst #2078).
 107. Rudnick J, Naor R, Moser F, **Phuphanich S**. A Dramatic and Prolong Response to Meningeal Gliomatosis. The 62nd Annual Meeting of American Academy of Neurology, Toronto, Canada, April 10-17, 2010, (Oral Poster Presentation) Neurology 74 March 2, 2010 Suppl 2 A595 (Abstr #IN10-2.002)
 108. **Phuphanich S**, Rudnick J., Chu R., Mazer M., Wang H., Serrano N., Richardson J., Wheeler C., Black K, Singh M., Yu J Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107). The 46th Annual Meeting of the American Society

of Clinical Oncology, Chicago, Illinois, June 6, 2010 Proc Am Soc Clin Oncol 28:15S (May 20 Supplement), 2010 (Abst #2097).

109. Reardon DA, Thurm H, Fink K, Giglio P., Shapiro W, LaRocca R., Mikkelsen T., **Phuphanich S.**, Portnow J, Schiff D., Phase I/II Study of BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma. The 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, June 6, 2010 Proc Am Soc Clin Oncol 28:15S (May 20 Supplement), 2010 (Abst #2590).